Targeting Lipid Metabolism for the Treatment of Age-Related Macular Degeneration: Insights from Preclinical Mouse Models

Michael Landowski and Catherine Bowes Rickman

Abstract

Age-related macular degeneration (AMD) is a major leading cause of irreversible visual impairment in the world with limited therapeutic interventions. Histological, biochemical, genetic, and epidemiological studies strongly implicate dysregulated lipid metabolism in the retinal pigmented epithelium (RPE) in AMD pathobiology. However, effective therapies targeting lipid metabolism still need to be identified and developed for this blinding disease. To test lipid metabolism-targeting therapies, preclinical AMD mouse models are needed to establish therapeutic efficacy and the role of lipid metabolism in the development of AMD-like pathology. In this review, we provide a comprehensive overview of current AMD mouse models available to researchers that could be used to provide preclinical evidence supporting therapies targeting lipid metabolism for AMD. Based on previous studies of AMD mouse models, we discuss strategies to modulate lipid metabolism as well as examples of studies evaluating lipid-targeting therapeutics to restore lipid processing in the RPE. The use of AMD mouse models may lead to worthy lipid-targeting candidate therapies for clinical trials to prevent the blindness caused by AMD.

Keywords: mouse models, lipid metabolism, complement, therapeutics, age-related macular degeneration, retinal pigmented epithelium

Introduction

Age-related macular degeneration (AMD) affects about 30% of Americans over age 70 and is the most common cause of irreversible blindness among elderly people in industrialized countries. AMD is characterized by the progressive deterioration of the macula, an anatomical region of the retina that contains the highest density of cone photoreceptors and is responsible for visual acuity. Currently, there are limited interventions that slow or prevent the progression of AMD to its blinding late stages, thus there is an urgency to identify therapies that prevent or delay its progression. AMD is a complex, progressive, retinal degenerative disease influenced by both environmental and genetic factors and is dependent upon advanced age. It is imperative to devise therapeutic strategies for AMD and curb its burden on societies since the prevalence of AMD is expected to substantially increase in the next decades.

An ideal strategy to treat AMD would involve targeting the early/intermediate “dry” stages before irreparable visual loss occurs in patients. The early stages of AMD are fairly benign and consist of impaired dark adaptation that corresponds to rod photoreceptor dysfunction, focal accumulation of intermediate-sized (63 to 125 μm diameter) lipid, lipoprotein, and protein-containing deposits known as drusen within Bruch’s membrane (BrM), and choriocapillaris dropout. Intermediate AMD comprises retinal pigmented epithelium (RPE) pigmentary changes and larger drusen (>125 μm diameter). As AMD progresses to its late stages, it is classified as either exudative or nonexudative AMD. The presence of choroidal neovascularization (CNV) characterizes the exudative or “wet” form of late AMD where the formation of immature blood vessels from the choroid advances into the RPE and subretinal space causing fibrosis and scarring and irreparable vision loss. The nonexudative or “dry” form of late AMD is distinguished by geographic
atrophy where there is central loss of RPE and photoreceptors without the presence of vascular leakage. Most of the AMD-afflicted population has early/intermediate or late “dry” AMD, while 10% of patients present with “wet” AMD.

Current therapies for AMD target pathologies associated with the wet form of AMD, whereas no therapies exist for early/intermediate dry AMD or geographic atrophy. The current gold standard for the treatment of wet AMD is intravitreal injection of anti-vascular endothelial growth factor (VEGF) antibodies, such as bevacizumab (Avastin) and ranibizumab (Lucentis) or the soluble decoy receptor targeting VEGF-A, aflibercept (Eylea). However, not all wet AMD patients respond well to anti-VEGF therapies. It is also possible for patients with exudative AMD to progress to late stages of nonexudative AMD even after anti-VEGF treatment.

Development of novel therapies targeting dry AMD should be facilitated by identifying and examining the pathobiological processes implicated in AMD. Inflammation, complement dysregulation, oxidative stress, extracellular matrix (ECM) remodeling, dysregulated lipid metabolism, and angiogenesis have been implicated as key pathobiological mechanisms underlying AMD development and progression. Polymorphisms in genes that regulate complement activation and lipid metabolism are among the biggest genetic risk factors for AMD. Strong evidence based on biochemical, genetic, and cell biological studies implicates the alternative pathway of complement in the development of AMD. Growing evidence from studies using preclinical AMD mouse models further supports an important role of dysregulated lipid metabolism in AMD-like pathology development in vivo and provides a potential link between complement factors and lipoprotein accumulation and clearance. In this review, we present an overview of mouse models of AMD, present new strategies for modulating lipid metabolism based on findings from AMD mouse model studies, and summarize studies that evaluated treatments focused on lipid metabolism in AMD mouse models. For more comprehensive reviews of lipid metabolism in AMD, we refer readers to these excellent reviews. In addition, we direct readers to this excellent review that highlights higher order animal models of AMD as these models will not be discussed in this review.

Associations of Dysregulated Lipid Metabolism with AMD

Risk factors for developing AMD include advanced aging, genetic variants, and environmental stressors. Advanced aging is the strongest associated risk factor for AMD (Fig. 1). An individual’s risk for developing AMD at

![Figure 1](image_url)

**FIG. 1.** Association of dysregulated lipid metabolism with AMD development and progression. **Left:** Normal, healthy retina. **Middle:** Retina with signs of benign aging such as loss of mitochondria, RPE pigmentation changes, and BLamD formation between the RPE and BrM. **Right:** Through a complex interplay between genetic variants and environmental factors, AMD can develop and progress in the aging retina. Classic pathological hallmarks of AMD include recruitment of subretinal immune cells, photoreceptor degeneration, RPE atrophy and loss, drusen (which start out as basal linear deposits), and form within the ICL of BrM, chorioidal atrophy, and CNV. Genetic and epidemiological studies of AMD patients revealed dysregulated lipid transport and metabolism as a key pathobiological mechanism behind AMD. Coding variants in APOE, LIPC, CETP, LPL, and ABCA1 are associated with AMD risk, but it is still unknown why particular variants are linked with disease risk. In addition, diets enriched in omega-6 fatty acids while those deficient in omega-3 fatty acids also increase an individual’s risk for AMD. It is widely accepted that omega-6 fatty acids promote, and omega-3 fatty acids dampen retinal inflammation. ABCA1, ATP-binding cassette subfamily A member 1; AMD, age-related macular degeneration; APOE, Apolipoprotein E; BI, basal infoldings; BLamD, basal laminar deposit; BrM, Bruch’s membrane; CETP, cholesteryl ester transfer protein; Choroid BM, chorioidal basement membrane; CNV, chorioidal neovascularization; EL, elastic layer; ICL, inner collagenous layer; LD, lipid droplet; LIPC, hepatic lipase; LPL, lipoprotein lipase; M, mitochondria; N, nucleus; OCL, outer collagenous layer; PG, pigment granule; Ph, phagosome; RPE BM, RPE basement membrane; RPE, retinal pigment epithelium.
TARGETING LIPID METABOLISM FOR THE TREATMENT OF AMD

age 55 is 0.7%, but this exponentially increases to 22.5% by the age of 80.32 Aging induces a number of changes in the retina, including loss of mitochondria,33 RPE pigmentation changes,34 and accumulation of lipid within BrM, a pentalaminar ECM that separates the RPE from its adjacent choroidal blood supply and acts as a basement membrane for the RPE and choroid (Fig. 1).34 The age-dependent accumulation of lipid in BrM is thought to contribute to the development of drusen.34 While the presence of a few small “hard” drusen or basal laminar deposits (BLamD) is a normal, nonvision-imparing part of aging, the deposition of large diffuse drusen, or basal linear deposits, in the macula is vision impairing and indicative of intermediate AMD.34

Lipid accumulation and cholesterol have long been implicated in AMD disease development.35,36 Historically, a role for lipids in AMD has been established through pathological examinations of drusen in human donor eyes.36 Immunofluorescence, mass spectrometry, and transcript studies of human donor eyes identified apolipoprotein E (ApoE) as a major drusen constituent.37–41 ApoE is a protein component of most lipoproteins, lipid-, and protein-containing complexes responsible for packaging cholesterol and fats from the circulation for transport to tissues and releasing cholesterol and lipids from tissues through reverse cholesterol transport. The function of ApoE in lipoproteins is to facilitate their cellular uptake as well as bind to extracellular matrices for efficient delivery and removal of lipids from cells.32 In addition to ApoE, a number of lipid species such as esterified cholesterol,40,43,44 unesterified cholesterol,40,44 phosphatidylcholine,40 triglycerides,40 sphingomyelin,40 and fatty acids,40 as well as other apolipoproteins40,41 have been identified as drusen components. Many of these drusen components are oxidized,45 and these oxidized lipids and proteins are believed to contribute to a proinflammatory environment that accelerates AMD development.46

The origin of ApoE-containing lipoproteins in drusen is from systemic sources through the circulation and from local synthesis by the RPE, although the relative contribution of each is not known. Circulating lipoproteins must enter and pass through BrM, which is thought to allow passive diffusion of high-density lipoproteins (HDLs) and low-density lipoproteins (LDLs) based on hydraulic conductivity and LDL diffusion studies using bovine BrM explants.37 Intriguingly, increased plasma HDLs48–52 and LDLs53 have been associated with increased risk for AMD and may directly impact drusen accumulation and growth. Evidence that locally derived ApoE-containing lipoproteins contribute to drusen biogenesis comes from studies showing that human RPE cells are capable of synthesizing and secreting ApoE.54,55 In addition, a cell culture model of drusen biogenesis developed by Johnson et al. using primary human RPE cells exposed to human serum that mimics several aspects of early AMD showed accumulation of drusen-like deposits that contain ApoE and other drusen-associated proteins.56

Genetic variants are strong contributors to AMD accounting for 28%–43% of AMD disease risk depending on the estimated prevalence of AMD in the population.18,57 Variants in genes involved in lipid metabolism include APOE. ApoE exists as 3 isoforms that differ at 2 amino acid positions: ApoE2 (Cys112, Cys158), ApoE3 (Cys112, Arg158), and ApoE4 (Arg112, Arg158).58 The APOE2 isoform is associated with increased risk for AMD while the APOE4 isoform is mildly protective against AMD.59–62 Variants in other genes involved in lipid metabolism that are associated with AMD risk include hepatic lipase (LIPC), cholesteryl ester transfer protein (CETP), and lipoprotein lipase (LPL), which are involved in HDL cholesterol metabolism, and ATP-binding cassette subfamily A member 1 (ABCA1) (Fig. 1).63–65 The importance of HDL cholesterol metabolism in the RPE is highlighted by a recent phenotypic study of mice with RPE-specific ablation of ABCA1 and ATP-binding cassette transporter G1 (ABCG1).66 The RPE-specific ablation of ABCA1 but not ABCG1 was sufficient to cause lipid accumulation in the RPE, degeneration of the RPE and photoreceptors, and visual loss in mice.66 Interestingly, the AMD-associated genetic variant of ABCA1 decreases its expression in RPE cells,66 ABCA1 and ABCG1 are critical exporters of cholesterol from cells,67 suggesting the molecular explanation of the risk associated with ABCA1 variants and AMD may be due to decreased export of cholesterol from RPE cells.

Environmental and lifestyle stressors modulate the effects of aging and genetic variants on AMD development. Cigarette smoking strongly influences the risk for AMD, whereas obesity, hypertension, sunlight exposure, and alcohol consumption are mildly associated with disease risk.68–73 A high-fat (HF) diet is an established risk factor for AMD74–76 and often used in AMD mouse model studies,20,21,77–84 Consuming diets with a high concentration of fish oils containing omega-3 fatty acids are related with a decreased incidence of AMD85–88 compared with increased incidence of AMD in individuals eating diets high in omega-6, monounsaturated, polyunsaturated, and trans unsaturated fatty acids (Fig. 1).86,87 It is largely unknown how these environmental stressors interact with advanced aging and genetics to influence AMD pathogenesis.

Models of AMD

AMD can be modeled using a variety of organisms that range from zebrafish to mice to nonhuman primates. Nonhuman primates are ideal models due to the presence of a macula, drusen in aged animals,89 and shared common AMD susceptibility genes such as age-related maculopathy susceptibility 2 (ARMS2)/HtrA serine peptidase 1 (HTRA1),90 but these animals are very costly to maintain and have a slow disease progression. Nonmammalian models like zebrafish are advantageous in that they produce large quantities of offspring and allow for easy assessment of eye phenotypes due to their transparent bodies in juveniles, but they differ from mammals in their retinal vasculature organization and develop photoreceptor degenerations beginning in the larval stage and not in the adult fish.91,92 Mice are the most routinely used model organisms for studying AMD due to their short life span, genetic and pharmacologic manipulability, inexpensive housing, and retinal architecture that is similar to humans. The mouse retina is particularly susceptible to the development of age-dependent retinal pathologies, such as decreased visual function,93,94 BLamD formation,95 RPE multinucleation,96 cataract formation,97 ectopic synapse development,98 and neuroinflammation,99,99 validating their usage in interrogating mechanisms associated with age-dependent retinal diseases like AMD.
The most commonly used mouse models in AMD research largely represent early and intermediate dry AMD, although there are a few models that aim to model wet or late dry AMD (Fig. 2 and Table 1). One important consideration for an AMD mouse model is the incorporation of advanced aging, as aging is the strongest risk factor for human AMD. Many early and intermediate dry AMD mouse models incorporate advanced aging, thus effectively incorporating the effect of chronic processes that drive the development of early/intermediate AMD pathology. Therefore, these models may not faithfully reflect the complex age-dependent pathological cues and/or mechanisms that cause AMD and may confound the interpretation of drug efficacy studies.

One exception is the wet AMD model using aged HTRA1-overexpressing mice where pathologies were observed at 1 year of age. An important issue to consider is that AMD-associated variants at chromosome 10q26 loci, where HTRA1 is located, have been shown to decrease HTRA1 expression, suggesting HTRA1-overexpressing mice may not represent the role of HTRA1 in AMD pathobiology. This is further supported by a recent article from the Hageman group showing that HtrA1 is specifically reduced as much as 50% in the RPE of humans with the ARMS2 risk allele. This appears to be due to disruption of a cis-acting regulatory element within the ARMS2 locus further supporting that augmentation, not inhibition, of HTRA1 is a rational therapeutic approach for AMD patients with the 10q26 risk allele.

A popular strategy for generating AMD mouse models has been to subject them to acute insults aimed at reproducing AMD-relevant environmental stressors and assessing retinal damage after a few days and/or weeks. Because oxidative stress has been implicated in AMD, many of these acute insults increase the oxidative stress burden in the eye. These include systemic sodium iodate treatment, intravitreal paraquat, oral hydroquinone, and blue light exposure (Fig. 2 and Table 1).

The most commonly used acute AMD mouse model is laser-induced CNV, which is meant to model wet or neovascular AMD (Table 1). Importantly, it has been a reliable animal surrogate in the development of therapeutics to treat wet AMD, including predicting the clinical efficacy of anti-VEGF therapy for wet AMD. Laser photocoagulation is used to disrupt BrM in laser-induced CNV, stimulating growth of new choroidal blood vessels toward the retina. The laser-induced CNV mouse model produces quick results within a few weeks, but it is more of a wound-healing model. Unlike in human CNV, the laser-induced CNV in rodents spontaneously regresses after a few weeks and there is considerable variation in outcome between mouse strains, genotypes, and age. Still, the laser-induced CNV mouse model has been widely used in studies evaluating therapies targeting components of lipid metabolism for...
| Mouse model                                                                 | Abbreviation       | Comments                                                                                                                                                                                                 | References |
|----------------------------------------------------------------------------|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Acid sphingomyelinase (ASMase) knockout (KO) mouse                         | ASMase−/−          | Deficiency of ASMase leads to age-dependent visual loss, photoreceptor degeneration, and increased RPE autofluorescence that correlates with decreased retinal sphingomyelin levels and increased eyecup autophagy. | 131        |
| Human apolipoprotein B100 (APOB100) mouse fed a high-fat (HF) diet         | APOB100~HF         | C57BL/6d mice that contain the full-length human APOB gene were fed a HF diet and aged to 12 months but no apparent phenotypic differences were observed between APOB100 mice fed a normal mouse chow and HF diet. | 77         |
| Apob100 mouse fed a low-fat (LF) diet                                       | Apob100~LF         | Mice with apob mutation that prevents the formation of the alternatively spliced Apob48 variant was used to evaluate LXRs agonists.                                                                      | 100,101    |
| Apolipoprotein E (Apoe) KO mouse fed a high cholesterol (HC) diet          | Apoe−−/− HC        | 4-5-week-old Apoe−/− mice were fed a HC diet for 25 weeks and had worsened retinal pathologies relative to controls.                                                                                 | 78,79      |
| Human apolipoprotein E isoform 4 (APOE4) mouse fed a high-fat, cholesterol-enriched (HFC) diet | APOE4~HFC         | Aged APOE4~HFC develop more severe AMD-like pathology than aged APOE2 and APOE3 mice fed a HFC diet.                                                                                                   | 80,81      |
| Aryl hydrocarbon receptor (Ahr) KO mouse                                   | Ahr−/−             | Chronic mouse model based on AHR activity and protein concentration decreases with age in human RPE cells.                                                                                             | 102        |
| C57BL/6J mouse exposed to cigarette smoke (CS)                             | C57BL/6J~CS        | 2-month-old C57BL/6J mice were exposed to cigarette smoke for 5 h a day and 5 days a week for 6 months that resulted in ultrastructural changes to BrM and RPE apoptosis.                                   | 132        |
| C57BL/6J mouse fed a HF diet                                               | C57BL/6J~HF        | 6-week-old C57BL/6J mice fed a HF diet for 30 weeks developed decreased ERGs, increased fundus abnormalities and thickened BrM.                                                                      | 82         |
| C57BL/6J mouse fed a high glycemic (HG) diet                               | C57BL/6J~HG        | 16-month-old C57BL/6J mice were fed a HG diet until 23.5 months of age and developed more AMD-like pathologies that correlated with changes in the microbiome.                                          | 103,104    |
| Complement membrane cofactor protein (Cd46) KO mouse                       | Cd46−/−            | Loss of CD46, a membrane regulator of complement activation, leads to age-dependent mice increases in RPE autofluorescence and BrM thickness as well as decreases in choroidal thickness in mice.            | 124        |
| C57BL/6J mouse immunized with carboxyethylpyrrole (CEP)-adducted BSA      | CEP immunized      | Chronic mouse model with increased inflammasome activation and increased proinflammatory macrophage infiltration.                                                                                  | 105        |
| Collagen-induced arthritis (CIA) in C57BL/6J mouse                         | CIA Induced C57BL/6J | Mouse model of systemic inflammation that had decreased laser-induced CNV lesion size but worsened RPE pathologies after sodium iodate treatment.                                                     | 135        |
| Ceruloplasmin (cp) and hephaestin (Heph) double KO mouse                   | Cp−/− Heph−/−      | Chronic mouse model in which pathologies result from increased oxidative stress from retinal iron overload as supported by the protection against pathologies with the iron chelator deferiprone.             | 106,107    |
| Complement factor h (Cfh) KO mouse                                         | Cfh−/−             | Absence of CFH leads to excess complement activation resulting in no reservoir of plasma complement proteins and subtle retinal damage in aged Cfh−/− mice.                                           | 108,109,137|
| Heterozygous Cfh KO mouse fed a HFC diet                                   | Cfh−/+~HFC         | Aged Cfh−/+~HFC provides the first multifactorial AMD mouse model suited to test the role of complement components on AMD-like pathology development such as CSa.                                             | 21         |

(continued)
| Mouse model                                                                 | Abbreviation       | Comments                                                                                           | References |
|----------------------------------------------------------------------------|--------------------|---------------------------------------------------------------------------------------------------|------------|
| Human complement factor H (CFH) Y402 and H402 mouse                        | CFH,Cfh^{−/−}      | Transgenic mice expressing the full-length human CFH gene encoding either the Tyrosine (Y) or Histidine (H) at amino acid 402 were crossed to Cfh^{−/−} mice to generate mice that produce only human CFH Y402 or H402 protein, respectively, which functions with mouse complement proteins. | 109        |
| Human complement factor H (CFH) Y402 and H402 mouse aged and fed a HFC diet | CFH~HFC            | Phenotypic differences in ocular phenotypes, circulating lipoproteins and ocular lipoproteins were noted between mice expressing equal concentrations of either the CFH Y402 or H402 variant. Only CFH-H/H develop AMD-like phenotype | 20         |
| Chimeric, transgenic Cfh mouse                                            | Chimeric Cfh       | Mouse Cfh was genetically modified to include short consensus repeat domains 6 through 8 of human CFH and included either the Y402 or H402 amino acid but no difference in phenotype was observed between mice expressing these variants. | 110        |
| Mutant Cfh and Complement factor P (fP) KO mouse                          | fH^{−/−},fP^{−/−}  | Mice with a premature stop codon in the end of exon 19 of the mouse Cfh gene that results in complement activation^{130} crossed to fP KO mice generated increased sub-RPE basal deposits at an early age. | 140        |
| C-X-C chemokine receptor type 5 (Cxcr5) KO mouse                          | Cxcr5^{−/−}        | Cxcr5^{−/−} mice have increased sub-RPE deposits containing amyloid beta and C3a^{111} that may result from disrupted PI3K/AKT signaling and FOXO1 upregulation. | 113        |
| Cxcr5 and nuclear factor-like 2 (Nrf2) double KO mouse                    | Cxcr5^{−/−},Nrf2^{−/−} | Combined deficiency of Cxcr5 and Nrf2 worsens AMD-like pathologies observed in both Cxcr5 and Nrf2 KO mice. | 141        |
| Lysosome-associated membrane protein-2 (Lamp2) KO mouse                   | Lamp2^{−/−}        | Absence of Lamp2 in mice leads to the acceleration of sub-RPE basal laminar deposits that contain extracellular matrix proteins, lipoproteins, and cholesterol. | 114        |
| Microtubule-associated protein 1 light chain 3 B (LC3B) KO mouse         | LC3B^{−/−}         | LC3B KO mice have increased phagosomes, decreased fatty acid oxidation, RPE lipid accumulation, and subretinal immune cell infiltration. | 142        |
| Nrf2 KO mouse fed a HF diet                                               | Nrf2^{−/−}~HF      | 12-month-old Nrf^{−/−} mice fed a HF diet for 16 weeks developed a more robust AMD-like phenotype that correlated with interleukin 17-producing γδ T cells. | 83         |
| Heterozygous peroxisome proliferator-activated receptor-γ coactivator 1z (Pgc1z) KO Mouse Fed a HF Diet | Pgc1z^{−/−}~HF | Combined Pgc1z heterozygosity and consumption of a HF diet leads to loss of choroidal fenestrations and increased expression of drusen-associated genes. | 84         |
| Pgc1z and Nrf2 double KO mouse                                            | Pgc1z^{−/−},Nrf2^{−/−} | Combined deficiency of Pgc1z and Nrf2 causes RPE abnormalities and subRPE basal deposits that correlate with damaged mitochondria and increased ER stress. | 143        |
| Peroxisome proliferator-activated receptor-βδ (Pparβδ) KO mouse         | Pparβδ^{−/−}       | Pparβδ deficiency leads to increased lipid accumulation and thickened BrM but attenuates laser-induced CNV lesion size. | 123        |
| RPE-specific ATP-binding cassette transporter A1 (ABCA1) and ATP-binding cassette transporter G1 (ABCG1) mouse | RPE^{−/−}Abca1;Abcg1 | Absence of ABCA1 and ABCG1 in the RPE leads to increased lipids within the RPE, causing RPE dysmorphogenesis, neuroinflammation, and photoreceptor degeneration. | 66         |
| Mouse model | Abbreviation | Comments | References |
|-------------|-------------|----------|------------|
| RPE-specific KO of RB1-inducible coiled-coil 1 (Rb1cc1) mouse | Rb1cc1-CKO | Loss of RBIC1 in mouse RPE leads to autophagy defects and pathologies, including RPE degeneration, subretinal immune cell infiltration, subRPE deposition of inflammatory and oxidatively damaged proteins, subretinal drusenoid deposits, and CNV that precedes neural retinal abnormalities. | 144 |
| Rod-specific tuberous sclerosis complex 1 (Tsc1) KO mouse | rodTsc1−/− | Mice with rod-specific Tsc1 ablation that leads to constitutive activation of mTORC1 and pathologies resembling those observed in early, late dry, and wet AMD. | 122 |
| Superoxide dismutase 1 (Sod1) KO mouse | Sod1−/− | Chronic mouse model with a susceptibility to oxidative stress damage as shown by increased retinal damage after an intravitreal injection of paraquat. | 115,116 |
| Superoxide dismutase 2 (Sod2) knockdown mouse | Sod2−/− | Chronic mouse model where Sod2 has been knocked down using a viral-delivered ribozyme and Cre-LoxP recombination that has been used to test the efficacy of RPE65-programmed bone marrow-derived cells in vivo. | 117,118 |
| Htra serine peptidase 1 (HTRA1) overexpressing mouse | HTRA1 | HTRA1 overexpression was achieved by RPE65 promoter-driven mouse Htra1,129 CMV-BEST1 hybrid promoter-driven human HTRA1 and CAG-driven mouse Htra1 expression in wild-type mice and resulted in pathologies after 1 year of age. | 119,128,129 |
| Htra serine peptidase 1 (HTRA1) overexpressing mouse exposed to cigarette smoke (CS) | HTRA1 ~ CS | 12-month-old HTRA1 overexpressing mice were exposed to cigarette smoke for 30 min per day, 5 days per week for 12 weeks, and resulted in increased CNV and sub-RPE basal deposits. | 119 |
| Laser-induced CNV | | Commonly used acute model that has been interrogated in multiple transgenic mice (i.e., Cfh−/−,137 Ahr−/−,147, and Cx3cr1−/−148 and used for testing novel therapies for wet AMD. | 127,149 |
| Polyethylene glycol (PEG)-induced CNV | | Subretinal injection of PEG, a complement activator, leads to CNV in mice 5 days postinjection and is dependent on complement activation. | 150 |
| Very-low-density lipoprotein receptor (Vldlr) KO mouse | Vldlr−/− | Mouse used to model retinal angiomatous proliferation. | 151 |
| Dicer knockdown mouse | Dicer−/− | Acute mouse model where Dicer has been knocked down by Cre-LoxP recombination and results in increased Alu mRNA and frank RPE cell death mediated by inflammasome activation. | 120,153 |
| Inducible Cre recombinase driven by the monocarboxylate transporter 3 promoter and Diphtheria toxin A (DTA) with LoxP-flanked stop codon double transgenic mouse | RPE(CreER)/DTA | RPE(CreER)/DTA mice have 60%–80% RPE cell death that results in ERG and retinal pathology and serves as a valuable model for stem cell-derived RPE transplantation studies. | 154 |
| Sodium iodate treatment | | Acute insult causing RPE damage resulting in RPE atrophy and death, retinal degeneration, and immune cell recruitment by 3 days postinjection. | 125,126,155 |
| Laser-induced RPE atrophy | | Acute mouse model with focal atrophic photoreceptors, abnormal RPE and BrM, visual loss, and neuroinflammation without signs of neovascularization. | 156 |
| Transmembrane protein 135 (Tmem135) transgenic (TG) mouse | Tmem135 TG | Overexpression of Tmem135 leads to fragmented mitochondria in RPE cells as well as progressive RPE degeneration and dysmorphogenesis without affecting visual function until 1 year of age in mice. | 121 |

(continued)
| Mouse model                                | Abbreviation | Comments                                                                                                                                                                                                 | References   |
|-------------------------------------------|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Acute models of AMD                       | Blue light exposure | Acute insult that results in damage to the neural retina that has been used to differentiate microglia and bone marrow-derived macrophages in the retina. | 158–160      |
|                                           | Intravitreal injection of paraquat | Acute insult that results in increased oxidative stress damage and subsequent damage to the neural retina that is used for antioxidant therapy studies. 16-month-old C57BL/6J female mice were given oral hydroquinone in their drinking water that resulted in the development of sub-RPE basal deposits. BALB/c albino mice treated with white light for 24 h leads to photoreceptor apoptosis and visual loss as well as immune cell infiltration that is worsened after CEP immunization. | 161          |
|                                           | Oral hydroquinone |                                                                                                                                                                                                          | 162          |
|                                           | White light exposure |                                                                                                                                                                                                          | 163          |
| Mouse models of inherited macular degeneration | ATP-binding cassette, subfamily A (ABCI), member 4 (Abca4) KO mouse | Mouse model of recessive Stargardt’s disease that is often used in studies on complement activation, lipofuscin, and novel drug development for AMD. | 166,167      |
|                                           | C1q and tumor necrosis factor related protein 5 (C1QTNF5) serine to arginine at amino acid 163 (S163R) knockin mouse | Mouse model of late-onset retinal degeneration generated by an introduction of the S163R mutation into the mouse C1QTNF5 gene as well as viral delivery of human C1QTNF5S163R to the RPE of C57BL/6J mice. | 168,169      |
|                                           | EGF-containing fibulin-like extracellular matrix protein 1 (Efemp1) arginine to tryptophan at amino acid 345 (R345W) knockin mouse | Mouse model of Malattia Leventinese/Doyne’s Honeycomb Dystrophy revealed a vital role of complement in sub-RPE deposit formation and replicated using cell culture. | 172,173      |
|                                           | Elongation of very-long-chain fatty acids protein 4 (Elovl4) five base pair deletion knockin mouse | Mouse model of dominant Stargardt’s disease characterized by defects in very-long-chain polyunsaturated fatty acids in the retina. | 175,176      |
|                                           | Metalloproteinase inhibitor 3 (Tmp3) serine to cysteine at amino acid 156 (S156C) knockin mouse | A mouse model of Sorsby’s dystrophy used in angiogenesis studies. | 178          |

AMD, age-related macular degeneration; BrM, Bruch’s membrane; CNV, choroidal neovascularization; ERG, electroretinography; LXR, liver X receptor; mTOR, mammalian target of rapamycin; RPE, retinal pigmented epithelium.
exudative AMD, such as omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), \textsuperscript{181-184} apolipoprotein A-I (ApoA1) and ApoAl-binding protein (AIBP), \textsuperscript{185} apolipoprotein M (ApoM), \textsuperscript{186} HDL eye drops, \textsuperscript{187} AREDS2 supplementation, \textsuperscript{188} atorvastatin, \textsuperscript{189} pitavastatin, \textsuperscript{190} and cytochrome P450 oxidase 2C (CYP2C) inhibition. \textsuperscript{191}

The use of mouse models of inherited macular degenerations may be advantageous to test preclinical AMD therapeutics due to their quicker onset, robust penetrance, and severe pathology development. A subset of mouse models were developed based on mutations in genes that cause inherited macular degenerations in humans, including C1q and tumor necrosis factor-related protein 5 (C1QTNF5) in late-onset retinal macular degeneration, \textsuperscript{168,169} EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1) in Malattia Leventinese/Doyne’s honeycomb retinal dystrophy, \textsuperscript{172,173} metalloprotease inhibitor 3 (TIMP3) in Sorsby’s fundus dystrophy, \textsuperscript{178} and ATP-binding cassette subfamily A member 4 (ABCA4) in autosomal recessive Stargardt disease (STGD1) or elongation of very-long-chain fatty acid protein 4 (ELOVL4) in autosomal dominant Stargardt macular dystrophy (STGD3). \textsuperscript{166,167,175,176} (Fig. 2 and Table 1). Inherited macular degenerations differ from AMD since they are caused by a genetic mutation and generally present earlier in life. \textsuperscript{192-196} Still, regardless of the different etiologies between these diseases, the mouse models of these macular degenerations recapitulate many of the cardinal features of their respective inherited macular degeneration and some features of AMD. \textsuperscript{166,168,172,173,175,176,178,197,198}

**Limitations of Mouse Models in AMD and Lipid Metabolic Research**

Although there are many advantages to using preclinical AMD mouse models, it is critical that AMD researchers be well informed of the potential confounders that might influence the interpretation of AMD mouse model studies. For example, there are genetic mutations within some mouse strains that can cause retinal degenerations such as the rd8 mutation in Crumbs homolog 1 (Crb1) \textsuperscript{199} and rd1 mutation in phosphodiesterase 6B (Pde6b). \textsuperscript{200,201} Before beginning any study, researchers should screen their mice to confirm the absence of these mutations in their colonies. Another important consideration of AMD mouse models is the genetic background of the mouse. It is becoming apparent that the phenotypes of murine disease models are heavily dictated by their mouse genetic background as observed with mouse models of Alzheimer’s disease. \textsuperscript{202} Lastly, environmental variation can also exert unwanted effects on AMD mouse model studies. Differences in normal mouse chow, microbiota, and stress levels can affect phenotypic outcome measures. \textsuperscript{203} Consideration, careful planning, and appropriate controls are crucial determinants for the success of any study using AMD mouse models. Here are some of the disadvantages of using preclinical AMD mouse models based on differences in the anatomy of their visual system and lipid metabolism.

**Differences between mouse and human retinas**

Notable distinctions exist between the mouse and human retina. For the most part, mouse and human eyes undergo similar early developmental programs, but these programs diverge to allow for the complex structure of the human retina. \textsuperscript{204} Importantly, mice do not possess a cone-dominant macular region but rather a rod-rich macular region that is similar to the rod-rich parafovea in humans. \textsuperscript{205} This similarity is an advantage of using the mouse retina for modeling early to intermediate AMD since this rod-rich region of the human macula is where macular degeneration is first detected. \textsuperscript{206} The cone-dominant macular region in the human retina allows for high visual acuity, but mice lacking this type of retinal structure have extremely low visual acuity that is equivalent to 20/2,000. \textsuperscript{207} Rods and cones have different energy demands \textsuperscript{208} and transcriptional profiles, \textsuperscript{209} thus, there could be difficulty in translating findings of ophthalmic drug studies in mice to humans.

A potent physiological difference between a mouse and human retina is the interaction between photoreceptors and RPE cells. RPE cells are tasked with delivering nutrients to photoreceptors and ingesting photoreceptor outer segment wastes. \textsuperscript{210} The central part of the mouse retina contains a higher density of photoreceptors than the central part of the human retina, equating to a higher proportion of photoreceptors to RPE cells in the central murine retina. \textsuperscript{205} In addition, there are more smaller and denser RPE cells in the center of the mouse retina than the central human retina. \textsuperscript{205} These differences suggest that murine RPE may have increased phagocytosis of photoreceptor outer segments and may explain transcriptional differences between mouse and human RPE, including increased expression of oxidative stress and outer retinal barrier genes. \textsuperscript{211} It has been shown that mice have higher basal metabolic rates than humans \textsuperscript{212} and could suggest higher metabolic rates in mouse RPE cells than human RPE cells. Furthermore, since RPE cells have coordinated metabolic relationships with both rod and cone photoreceptors, \textsuperscript{213} it is plausible that there are variations in the metabolic ecosystem within the murine retina versus human retina and may confound therapeutic studies, especially those focusing on metabolism.

**Differences between mouse and human lipid metabolism**

Mice and humans have similar expression of genes involved in lipid metabolism within the retina, \textsuperscript{214,215} but it is unknown if there are differences between lipid metabolic functions between mouse and human RPE. One important expression difference between these species is the absence of CETP in the mouse. \textsuperscript{216} CETP facilitates the transfer of cholesterol between HDL to very-low-density lipoprotein (VLDL) and LDL. \textsuperscript{217} Because of the CETP deficiency in mice, most plasma cholesterol is confined to HDL particles. \textsuperscript{218} This is in stark contrast to humans where most plasma cholesterol is found in LDL particles. \textsuperscript{218} Recapitulating the plasma lipid profiles of humans in mice can be achieved by diet intervention but often these diets do not represent typical diets consumed by humans. Strikingly, regardless of the absence of CETP and diet intervention, both mice and humans have comparable lipoprotein proteomes that may indicate similar functions of lipoproteins between mice and humans. \textsuperscript{218} Lastly, differences in transcription factors involved in lipid metabolism between mice and humans may influence lipid-targeting drug studies in AMD mouse models. \textsuperscript{219} Thus, caution is warranted when extrapolating conclusions from lipid metabolism, notably with regard to cholesterol metabolism, studies in mice to humans.
Translatability of mouse studies to the clinic

The anatomical differences between the mouse and human retina have called into question the usefulness of mice in evaluating therapies for AMD since these studies may not translate well to the clinic. However, it is important to remember that AMD mouse models are only 1 step in the bench-to-bedside pipeline for translating basic research to clinical treatments (Fig. 3). We strongly advocate for the validation of preclinical AMD mouse model studies with other models of AMD. In parallel with the mouse models presented in this review, advances have been made in cell culture systems such as fetal human RPE, induced-pluripotent stem cell-derived RPE, primary porcine RPE, and retinal organoids that allow for confirmation of mouse study findings in human cells (Fig. 3). Ultimately, any therapeutic showing promising effects should be tested in higher order animal models of AMD, including rats, rabbits, pigs, or nonhuman primates (Fig. 3). No model of AMD has represented the full complex spectrum of AMD but combining multiple models together is essential for the translating results from mouse studies to humans.

Devising and Testing Lipid Metabolism-Targeting Therapies in Preclinical AMD Mouse Models

Numerous AMD mouse models are available to researchers, but it can be a daunting task to best leverage these models to design and determine drug efficacy of therapies targeting lipid metabolism. We propose 3 major therapeutic goals based on previously published AMD mouse model studies: (1) clearance of pathogenic lipid or protein components in sub-RPE deposits, (2) restoration of lipid processing in the RPE and BrM, and (3) preservation of lipid oxidative pathways (Fig. 4). In this study, we will discuss support for these strategies.

Clearance of pathogenic lipid or protein components in Sub-RPE deposits

Testing therapies directed at preventing the formation and/or accumulation of BLamDs in AMD mouse models is a good use of these models with the caveat that these deposits are not completely analogous to pathogenic drusen in AMD, such that therapies that work in these preclinical models may not necessarily translate well to human clinical trials. In support of this approach, it is important to note that many drusen constituents are found in BLamDs, including complement components, apolipoproteins, amyloid beta, extracellular membranous debris, and long-spaced collagen. Targeting specific components within BLamDs has led to amelioration of AMD-like pathologies in AMD mouse models. For example, aged transgenic APOE mice with targeted replacement of mouse ApoE with human APOE4 develop an AMD-like ocular phenotype, including...
decreased visual function, CNV, RPE damage, and BLamD accumulation after an 8-week high-fat, cholesterol-enriched (HFC) diet.80 APOE4 is associated with decreased risk for AMD in humans but the pathogenicity caused by the E4 allele in aged mice fed a HFC diet is unknown. 59–62

The BLamDs of APOE4–HFC mice contain complement activated products and amyloid-beta.81 Targeting amyloid beta with a systemic anti-amyloid-beta immunotherapy prevented amyloid-beta accumulation, sub-RPE complement activation, and AMD-like pathologies, although there was no change in BLamD load.81 Preventing the accumulation of toxic inflammatory components within drusen-like amyloid beta may be a viable therapeutic approach for AMD. However, a humanized monoclonal antibody against amyloid beta was tested in a clinical trial for the treatment of geographic atrophy but it failed to slow the geography atrophy enlargement in patients,225 indicating not all therapies assessed in mice are translatable to human diseases. Still, it should be noted that the anti-amyloid antibody, RN6G, which showed efficacy in the mouse and targets the c-terminus of both Ab40 and Ab42 was not the one tested in clinical trials.81

Similar to amyloid beta, oxidized lipids can be pathogenic to RPE cells.26 A therapeutic strategy for targeting inflammatory lipids in AMD has emerged from studies of AMD mouse models with varying complement factor H (CFH) activity.20,21,138 CFH is a major AMD susceptibility gene226–229 that functions as the main soluble regulator of the alternative complement pathway by serving as a cofactor for factor I-mediated proteolytic inactivation of C3b230 and accelerating the decay of the C3 convertase that is responsible for the initial activation and propagation of the complement cascade.231 The importance of CFH in regulating the formation of the C3 convertase is exemplified by the absence of intact plasma C3 in Cfh knockout (Cfh−/−) mice due to uncontrolled C3 cleavage.21,232

In addition to its canonical functions, we have found that CFH can bind and decrease adherence of ApoE- and ApoB-containing lipoproteins to BrM.21 To examine the
significance of impaired CFH binding to lipoproteins in vivo, C57BL/6J, Cfh heterozygous (Cfh+/−), and Cfh−/− mice were aged to ninety weeks and then fed a HFC diet for 8 weeks to exacerbate the subtle AMD-like phenotype seen in aged Cfh−/− mice.21,108,109 Consumption of a HFC diet leads to increased circulating lipoproteins in mice.23 Both aged Cfh−/− and Cfh+/− mice accumulate sub-RPE basal deposits in response to the HFC diet.21 Notably, only the aged Cfh−/− and not the Cfh+/− null mice fed a HFC diet, developed sustained vision loss and RPE damage.21 Aged Cfh−/− mice may be protected against HFC-induced ocular damage from pathogenic sub-RPE basal deposits because they lack a reservoir of complement components and they display increased expression of membrane-bound complement regulators in the posterior eye, whereas Cfh−/− mice possess an intact complement system, but express only half the levels of Cfh as wild-type mice.21,234,235

CFH also acts to regulate RPE-derived lipoprotein accumulations in BrM. Evidence for a unique RPE-derived lipoprotein comes from biochemical assessments of human donor eyes.23,236 RPE cells possess the machinery required to generate lipoproteins237 and have been validated by detecting secreted lipoproteins in the media of RPE cell cultures.236–238 Our recent study of transgenic mice expressing equal amounts of the full-length normal human CFH Y402 versus the AMD-risk-associated CFH H402 variant on a Cfh null background (CFH-Y/0 and CFH-H/H, respectively) revealed a correlation between RPE-derived lipoproteins and pathologies.20 The CFH Y402H polymorphism is one of the most replicated genetic variants associated with AMD risk.226–229 So these mice were developed to test the in vivo effect of the Y402H CFH risk variant on AMD pathobiology.20,109 CFH-Y/0 and CFH-H/H mice were aged to 90 weeks on a normal mouse chow diet (ND) and then switched to a HFC diet for 8 weeks to test for an AMD phenotype as aging and the consumption of a HFC diet are sufficient to elicit AMD-like pathology development in Cfh heterozygous mice and APOE4-targeted replacement mice.21,80 Only the old CFH-H/H mice fed HFC (CFH-H/H ~HFC) developed AMD-like pathologies.20

Quantitation of plasma lipoproteins in these mice revealed decreases in plasma LDLs and its markers, apolipoprotein B100 (ApoB100), and ApoE in aged CFH-H/H ~HFC mice compared with aged CFH-Y/0 mice fed HFC (CFH-Y/0 ~ HFC), but no change in any other lipoprotein class.20 Strikingly, however, biochemical analyses revealed that changes in eyecup apolipoproteins correlated with the AMD-like phenotype seen in the CFH-H/H ~ HFC, where apolipoproteins B48 (ApoB48) and A1 (ApoA-1) are elevated in the RPE/choroid of the aged CFH-H/H ~ HFC mice compared with age-matched control CFH-Y/0 after an 8-week HFC diet.20 Thus, we are the first to establish a functional consequence of the Y402H polymorphism in vivo, promoting AMD-like pathology and affecting lipoprotein levels in aged mice.20

The identity of molecular pathways involved in RPE lipoprotein synthesis and secretion are largely unknown, but insight may be gleaned from a dietary intervention study using aged CFH-H/H mice performed in our laboratory. Diets with similar macronutrient composition as the HFC diet previously used, which either had the dietary cholesterol removed (HF) or the fat removed [high cholesterol (HC)], were used to test the role of dietary cholesterol and fat on circulating lipoprotein and visual function in aged CFH-H/H mice. Aged CFH-H/H mice consuming a HFC or HC diet have increased chylomicron (CM)-, VLDL-, and LDL-containing cholesterol compared with aged CFH-H/H mice after a ND or HF diet (Fig. 5A). The area under each lipoprotein curve was calculated and the confirmed levels of these lipoproteins were statistically different between these groups (Fig. 5B). Visual function of aged CFH-H/H mice was assessed by scotopic electroretinography (ERG) after the consumption of an 8-week HF or HC diet.21 Using another cohort of aged CFH-H/H mice, these mice developed a similar decrease of scotopic ERG b-wave responses after the consumption of an 8-week HFC diet (Fig. 5C), as previously described.20 No change was observed in aged CFH-H/H ~ HF mice relative to aged CFH-H/H ~ ND mice (Fig. 5D). Notably, aged CFH-H/H ~ HC mice developed significantly attenuated ERG b-wave responses compared with aged CFH-H/H ~ ND mice (Fig. 5E).

The correlation of decreased visual function with consumption of dietary cholesterol in aged CFH-H/H mice fed a HC diet but not when fed a HF diet, supports the notion that therapeutic strategies targeting cholesterol intake through the small intestine (such as ezetimibe) may prevent visual loss in aged CFH-H/H ~ HFC mice. Ezetimibe interacts with the Niemann Pick C1-like intracellular cholesterol transporter 1 (NPC1) to prevent cholesterol uptake by intestinal enterocytes and thereby lowering the level of plasma LDLs containing cholesterol.239 Ongoing studies are examining whether ezetimibe could mimic the effects of dietary modulation in aged CFH-H/H mice and if HFC diet-induced increases in eye cup ApoB48 and ApoA-1 in aged CFH-H/H mice is influenced by dietary cholesterol.

ApoA-1 is a major protein constituent of HDL, a lipoprotein associated with AMD risk.48–51 In the posterior eye, the major site of interaction between CFH and HDL occurs at heparan sulfation within BrM.22,240 We postulate that augmenting CFH concentrations or soluble heparan sulfate in the posterior eye may prevent toxic accumulations of lipoproteins such as HDL in BrM and protect against RPE damage and death. In support of this, treatment of BrM explants from human donor eyes with short heparan sulfate oligosaccharides or an ApoA-1 mimetic was sufficient to remove lipoproteins from BrM.21 In addition, aged nonhuman primates that got an intravitreal injection of an ApoA-1 mimetic had less neutral lipid, esterified cholesterol, and activated complement components in BrM than placebo-treated controls.241 Pharmaceutical interventions aimed at lipoprotein binding in BrM may be effective in the treatment of AMD and should be considered in future studies involving AMD mouse models.

Restoration of lipid processing in the RPE and BrM

Restoration of pathways that the RPE cells use to process lipids could be a means to therapeutically target lipid metabolism in AMD. For example, multiple transcription factors, including sterol regulatory element-binding proteins (SREBPs),242 liver X receptors (LXRs),243 retinoid X receptors (RXRs),244 and peroxisome proliferator-activated receptors (PPARs)245 participate in intracellular lipid homeostasis. The SREBP, LXR, RXR, and PPAR pathways are present in RPE cells100,123,215 and their importance in lipid homeostasis of the RPE is supported by reports of visual loss and lipid deposition in mice lacking LXRA and PPAR β/δ signaling.100,125
In a study aimed at determining if activating LXRs can prevent AMD-like pathology development, 3-month-old mice with a mutation in apolipoprotein B100 (apob100) that prevents the formation of its alternative splice variant apolipoprotein B48 (apob48) were fed a low-fat diet for 5 months and given GW3965, an LXR agonist. Limiting expression to only ApoB100 in mice increased LDL triglyceride and cholesterol levels, resembling lipoprotein profiles in humans. As a consequence of this metabolic change, age-related progression of lipid deposition occurs in the BrM of apob100 mice but no other pathologies were noted in these animals. GW3965 treatment improved hypopigmented regions in fundus images, dampened neuroinflammation, and decreased lipid deposition in the apob100 mice after the 5-month low-fat diet. Differences in the ocular phenotypes of the apob100 mice may be explained by the standard mouse chow and low-fat diet consumed by mice in these 2 studies. More investigations of LXR agonists and other agents modulating transcription factors in other AMD mouse models are needed to confirm the promising results after treating apob100 mice with GW3965.

Another pathway critical for lipid metabolism within the RPE is autophagy, a conserved catabolic pathway induced under cellular stresses. Autophagy is increased in RPE cells of aged non-AMD eyes, but decreased in RPE cells of human donor eyes diagnosed with AMD. Mice with decreased autophagy such as microtubule-associated protein 1 light chain 3 B (LC3B) knockout, lysosomal-associated membrane protein 2 (Lamp2) knockout, and RPE-specific RB1-inducible

**FIG. 5.** Dietary intervention effects on plasma lipoprotein levels and visual function of aged CFH-H/H mice. Male CFH-H/H mice over 90 weeks of age, housed conventionally and maintained on ND (Isopura 5001; Prolab) were either continued on ND or switched to a HFC diet (Envigo #88051), HF diet (Envigo #98232) or HC diet (Envigo #91342) for 8 weeks. All mice were negative for the rd8 mutation. Protocols for FPLC fractionation, cholesterol quantification, ERG, and statistical analysis are described in Landowski et al. (A) FPLC fractions of male aged CFH-H/H mice after an 8-week ND, HFC, HF, and HC diet. (B) Averages of the area under the FPLC curve for aged male CFH-H/H mice after an 8-week ND, HFC, HF, and HC diet. Consumption of dietary cholesterol increases CM/VLDL and LDL cholesterol fractions in aged male CFH-H/H mice relative to the ND- and HF-fed groups. (C–E) Visual function in aged male CFH-H/H mice after an 8-week ND, HFC, HF, and HC diet. Analysis of scotopic ERG b-wave responses reveals statistically lower b-wave amplitudes in aged CFH-H/H mice fed a HFC and HC diet compared with ND-fed controls. Data are presented as fitted lines of the average. Mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001. CFH, complement factor H; CM, chylomicron; ERG, electroretinography; FPLC, fast protein liquid chromatography; HC, high cholesterol with no added cocoa butter fat; HDL, high-density lipoprotein; HF, high fat with no added cholesterol; HFC, high-fat, cholesterol-enriched; LDL, low-density lipoprotein; ND, normal mouse chow diet; nd, not detected; VLDL, very-low-density lipoprotein.
coiled-coil 1 (Rbl1cc1) knockout mice have lipid accumulations within the RPE.142,144 As a consequence, these mouse lines develop visual loss, migration of immune cells into the subretinal space, and subRPE deposits.114,115,142,144 Studies utilizing RPE cell cultures identified a synthetic lignan secoisolariciresinol diglucoside, LGM2605,249 and flubendazole250 as inducers of autophagy that were able to reduce intracellular RPE lipid levels. Testing these therapies in mice with increased RPE lipid accumulation like RPE-specific ABCA1 and ABCG1 knockout mice66 could be an effective means testing if targeting autophagy may be a therapy for AMD.

Preservation of lipid oxidative pathways

Another possible intervention is to sustain the lipid oxidative function of RPE cells through preservation of mitochondrial health. Mitochondria are critical organelles required for the breakdown of fatty acids for ATP production through beta-oxidation251 and regulation of reactive oxygen species that, when in excess, leads to lipid peroxidation.252 With age, mitochondrial function declines and impacts retinal homeostasis.15 Multiple AMD mouse models are based on mitochondrial dysfunction, including the Tmem135 transgenic (Tmem135 TG)121 and superoxide dismutase 2 knockout (Sod2−/−).117,118,253 It is possible that other mouse models may have mitochondrial impairment such as the DICER1-deficient mice.120,152,153 Not only is there a consequence of an accumulation of Alu elements in DICER1-deficient mice, they also have decreased mitochondrial genome-encoded small RNAs and consequent reduced mitochondrial gene expression.254 RPE degeneration is a common feature in these AMD mouse models.117,118,120,121,153,253,254 The RPE degeneration in these models phenocopies mice with RPE-specific ablation of mitochondrial transcription factor A (Tfam)255 and global knockout of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (Pgc1α),256 proteins required for mitochondrial biogenesis.

The RPE-specific Tfam knockout mouse have increased activation of the mammalian target of rapamycin (mTOR) pathway,255 a pathway crucial for nutrient sensing and homoeostasis.257 Abnormal mTOR activation can cause RPE degeneration258 but inhibiting mTOR in mice with RPE-specific ablation of TFAM or in mice treated with sodium iodate, alleviates RPE pathologies.255 Furthermore, activation of mTOR signaling through ablation of tuberous sclerosis complex 1 (Tsc1) in rod photoreceptors leads to RPE abnormalities.122 Conversely, activating mTOR in mouse models of retinitis pigmentosa is sufficient to reduce cone photoreceptor cell death,259–262 whereas inhibiting mTOR through rapamycin can decrease retinal vascularization and lead to hypoxia.263

One important aspect of the mTOR pathway is its ability to coordinate protein synthesis.264 One study mimicked inhibition of the mTOR pathway by administering anisomycin, which curbs eukaryotic protein synthesis, to rd16 and wild-type C57BL/6J mice.265 The rd16 mice had accelerated retinal degeneration, whereas wild-type mice developed retinal pathologies after anisomycin treatment.265 Restoring mitochondrial function, rather than targeting the mTOR pathway, may be a safer avenue for an AMD therapy, as it is less likely to damage other nearby ocular tissues.

Lipid Metabolism-Targeting Therapies Tested in Preclinical AMD Mouse Models

A fraction of the preclinical AMD mouse models (Fig. 2 and Table 1) has been utilized to evaluate lipid metabolism-targeting therapies. These therapies include desipramine, TO901316, docosahexaenoic acid (DHA), apolipoprotein mimetics, and statins (Table 2). In this study, we present published studies on these therapies as they offer perspectives on potential treatments for AMD.

Desipramine and TO901316

ABCA4 is a member of the ABC transporter family found on rod and cone photoreceptor outer segments.266–268 It is responsible for the clearance of all-trans-retinal from the disc membranes after phototransduction through the transport of N-retinylidene-phosphatidylethanolamine (PE), a product of the reaction of all-trans-retinal with PE.269 If N-retinylidene-PE is not removed from the disc membranes, N-retinylidene-PE can react with all-trans-retinal to form toxic accumulations of N-retinylidene-N-retinylethanolamine (A2E) and other bisretinoids in the RPE.269 Ablation of the murine Abca4 gene recapitulates STGD1-like phenotypes in mice, including age-dependent vision loss, delayed dark adaptation, increased retinal PE, deposition of A2E in the RPE, and additional toxic phototransduction byproducts.166,270,271

The spatial distribution of lipids in Abca4−/− RPE detected through a combination of matrix-assisted laser desorption ionization and Fourier transform ion cyclotron resonance imaging mass spectrometry reveals increases in cis-monooacylgllycerol phosphate (BMP) lipid species.272 BMP lipid species are commonly observed in endosomal/lysosomal storage diseases and regulate cholesterol levels in endosomes.273 Kaur et al. reported enlarged early endosomes in the RPE of Abca4−/− mice that allow more extracellular complement component 3 (C3) intake and activation of the C3-proteolytic cleavage product, C3a.274 Inhibiting acid sphingomyelinase with desipramine can decrease the size of early endosomes and prevent C3a activation in Abca4−/− RPE.274 Promoting cholesterol efflux with a LXR agonist, TO901316, can mimic the effects of desipramine on early endosome size in the Abca4−/− RPE.274 Decreasing the size of early endosomes in the RPE may be a viable therapeutic strategy for AMD, although more phenotypic work is needed to determine the functional effects of desipramine and TO901316 on the RPE in Abca4−/− mice and other models with RPE pathologies.

DHA treatment

Mutations in ELOVL4 are known to cause mislocalization and aggregation of ELOVL4 from the endoplasmic reticulum to other organelles in photoreceptors leading to STGD3.275,276 ELOVL4 is a fatty acid elongase that preferentially uses eicosapentaenoic acid (EPA) as a substrate to generate very-long-chain polyunsaturated fatty acids (VLC-PUFAs).277 To model STGD3, researchers identified a 5 base pair deletion in ELOVL4 of a STGD3 patient195 and generated transgenic mice expressing ELOVL4 with either the same 5 base pair deletion in human ELOVL4175 or mouse ELOVL4.176 Regarding the efficacy of omega-3 VLC-PUFAs as a treatment for STGD3, a recent long-term clinical study testing diets supplemented with omega-3
| AMD mouse model | Retinal pathologies observed in model                                                                 | Pharmacological treatment | Mode of action | Observed effects due to pharmacological treatment | References |
|-----------------|------------------------------------------------------------------------------------------------------|---------------------------|----------------|-----------------------------------------------|------------|
| 5-month-old Abca4<sup>−/−</sup> | • Delayed dark adaption  
• Elevated PE in outer segments  
• Increased A2E in RPE  
• RPE vacuolization  
• Increased retinal all-trans-RAL after light exposure  
• Increased A2E and lipofuscin granules in RPE  
• Cholesterol and ceramide accumulation in RPE  
• Increased early endosome number and size  
• Augmented complement activation | 3 Intraperitoneal injections of desipramine for 4 weeks | Inhibitor of ASMase that prevents ceramide production | • Decreased early endosome volume and number in RPE  
• Prevented C3a activation and signaling in RPE  
• Decreased early endosome volume and number in RPE | 274 |
| 3 Intraperitoneal injections of TO901316 for 4 weeks | LXR agonist | 274 |
| Various aged Elovl4<sup>mut/−</sup> | • Presence of fundus abnormalities  
• Photoreceptor degeneration  
• Decreased scotopic ERG a-wave and b-wave  
• Increased lipofuscin and A2E in RPE  
• Loss of synapses  
• Neuroinflammation  
• Extensive inner retinal remodeling | Dietary DHA supplementation for various lengths of time | C22:6n-3 fatty acid that has anti-inflammatory, anti-angiogenic and antiapoptotic effects | • Preservation of ERG c-wave in 6-month-treated mutant mice  
• Preservation of cone function in 12-month-treated mutant mice  
• Decreased A2E levels in 18-month-treated mutant mice  
• Decreased BrM thickness  
• Decreased esterified cholesterol deposition in BrM  
• Decreased retinal thinning  
• Prevented photoreceptor degeneration  
• Reduced cleaved caspase-3 in retina | 280a |
| 10-month-old Apoe<sup>−/−</sup> | • Increased implicit time for scotopic b-wave  
• Decreased ERG oscillatory potential amplitudes  
• Decreased ONL nuclei number  
• Thicker BrM  
• Increased retinal cholesterol  
• RPE degeneration  
• Photoreceptor degeneration  
• Neuroinflammation | Single intravitreal injection of 4F | APOA1 mimetic with anti-inflammatory and antiatherogenic properties | • Decreased prevalence of fundus abnormalities  
• No accumulation of lipids  
• Decreased RPE vacuolization  
• No deposition of heterogenous Debris below the RPE  
• Decreased BrM thickness | 82 |
| Intravenous injection of sodium iodate in 6-week-old C57BL/6J | | | | |
| 6-week-old C57Bl/6J ~ 30-week HF diet | • Presence of fundus abnormalities  
• Decrease of scotopic ERG a-wave and b-wave  
• Accumulation of lipids  
• RPE vacuolization  
• Deposition of heterogenous debris below the RPE  
• Thickened BrM thickness | Dietary simvastatin treatment for 30 weeks | Inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase that lowers endogenous cholesterol synthesis | "No beneficial effect was seen in a different study using a different Elovl<sup>mut/−</sup> mouse after a dietary DHA supplementation."<sup>279</sup> |

ApoA1, apolipoprotein A-I; APOJ, apolipoprotein J; ASMase, acid sphingomyelinase; DHA, docosahexaenoic acid; PE, phosphatidylethanolamine.
VLC-PUFAs, such as EPA and DHA, in STGD3 patients found no changes in the disease progression.\textsuperscript{278} Dietary DHA supplementation was also tested in mice with a mutant \textit{ELOVL4} allele but these studies yielded conflicting results.\textsuperscript{279,280} This could be due to the differential effect of the mutant \textit{ELOVL4} and \textit{Elov}4 allele on VLC-PUFA synthesis in the mouse retina. Only the mice with a mutant \textit{Elov}4 allele displayed a 50\% reduction in retinal VLC-PUFAs.\textsuperscript{174} Further studies have confirmed the essential role of \textit{ELOVL4} in retinal VLC-PUFA synthesis by ablating \textit{Elov}4 in cone and rod photoreceptors.\textsuperscript{281} Therefore, it would be important to test if DHA supplementation could be a viable therapeutic strategy in other mouse models of disrupted \textit{ELOVL4} function. This is especially important since DHA was added to the AREDS2 formulation and could explain why there was no reduction in AMD risk with the AREDS2 formulation.\textsuperscript{282}

\textbf{Apolipoprotein mimetics}

Repurposing lipid-lowering pharmacologic agents that have been effective in other diseases may be beneficial to treat AMD. For example, a major risk factor for cardiovascular disease is increased LDL and decreased HDL.\textsuperscript{283} The opposite has been shown for AMD where increased HDL has emerged as a major risk factor.\textsuperscript{48-51} One possible strategy to treat cardiovascular disease is to promote HDL function through ApoA1 mimetics. HDL particles that harbor ApoA1 are critical for reverse cholesterol transport, which removes lipids from cells and provides anti-inflammatory protection.\textsuperscript{284} ApoA1 mimetics vary in peptide length and promote reverse cholesterol transport and are anti-inflammatory.\textsuperscript{285} However, the effectiveness of ApoA1 mimetics as a cardiovascular disease treatment has been variable with some reports indicating no beneficial changes in patients.\textsuperscript{286-288} and others describing increased HDL function in patients.\textsuperscript{289}

To determine if ApoA1 mimetics could be effective against AMD, 10-month-old \textit{Apoe}\textsuperscript{-/-} mice were treated with a single intravitreal injection of the ApoA1 mimetic, 4F, and assessed 30 days postinjection for changes in BrM.\textsuperscript{290} 4F mimetic treatment sufficiently lowered esterified cholesterol and prevented ultrastructural changes in \textit{Apoe}\textsuperscript{-/-} mice.\textsuperscript{290} In addition, based on our findings of increased ApoA1 in \textit{CFH}+\textit{H}/\textit{H}+\textit{H}~HFC mice, we tested the ApoA1 mimetic 5A for 8 weeks in \textit{CFH}+\textit{H}/\textit{H}~HFC and were able to block HFC diet-induced changes in their plasma HDL proteome.\textsuperscript{53} We are currently testing whether the ApoA1 5A mimetic treatment correlate with changes in visual function that occur in both \textit{Apoe}\textsuperscript{-/-} and \textit{CFH}+\textit{H}/\textit{H} after a HF, cholesterol-enriched diet in these genotypes.\textsuperscript{20,78}

Other apolipoprotein mimetics have been tested in preclinical AMD mouse models such as the hybrid ApoE and apolipoprotein J (ApoJ) mimetic, HM-10/10 in the intravenous sodium iodate treatment model of geographic atrophy.\textsuperscript{291} Treatment of \textit{C57BL/6} mice with a diet chow containing HM-10/10 after induction of sodium iodate-induced RPE injury was sufficient to partially protect the retina and prevent caspase-3 cleavage in RPE cells.\textsuperscript{291} Since recruitment of immune cells is a major consequence of sodium iodate injury in the retina,\textsuperscript{292} it would be interesting to investigate whether HM-10/10 can reduce sodium iodate-induced immune cell recruitment to the retina as this frequently occurs in AMD mouse models and AMD-afflicted eyes.\textsuperscript{293}

\textbf{Statins}

Pharmaceuticals that could work for AMD and revolutionized the treatment of cardiovascular disease are statins, a class of lipid-lowering agents inhibiting the activity of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase to increase the uptake of LDLS and decrease plasma cholesterol.\textsuperscript{294} A recent pilot study, which was randomized and placebo controlled, showed that taking simvastatin (40 mg/day) slowed progression of nonadvanced AMD especially for those with the \textit{CFH} Y402H genotype.\textsuperscript{295} Additionally, an open-label prospective pilot multicenter clinical trial found that a high dose of statins given to 26 patients resolved drusenoid pigment epithelial detachments and improved visual acuity without any progression to RPE atrophy or CNV formation.\textsuperscript{296} However, the potency of statins as a treatment for AMD is controversial as evident by varying conclusions of case/control cross-sectional studies where statin usage had a beneficial,\textsuperscript{297-299} worsened,\textsuperscript{300,301} or no effect in AMD.\textsuperscript{302-314}

To determine efficacy in an animal model, female \textit{C57BL/6} mice were orally treated with simvastatin, atorvastatin, rosuvastatin, and pravastatin at similar concentrations where simvastatin had the highest accumulation in the retina.\textsuperscript{315} Oral gavage of simvastatin led to a 24\% reduction in retinal cholesterol content,\textsuperscript{315} suggesting simvastatin can inhibit cholesterol synthesis in the retina. \textit{C57BL/6} mice fed a HF diet for 30 weeks were treated concurrently with simvastatin to evaluate the effect of simvastatin on retinal pathology development.\textsuperscript{316} Simvastatin treatment decreased fundus abnormalities and BrM thickness, but did not significantly ameliorate visual function induced by the 30-week HF diet regime.\textsuperscript{317} The absence of a visual function change could be due to an upregulation of cluster of differentiation 36 (CD36), an oxidized LDL receptor critical for ingestion of photoreceptor outer segments,\textsuperscript{316} in the mouse retina.\textsuperscript{315} Intake of oxidized LDL in the posterior eye can lead to increased expression of genes regulating oxidative stress, inflammation, and angiogenesis,\textsuperscript{317-320} as well as an increase in the number of apoptotic RPE cells.\textsuperscript{317,321,322} Further analysis of the \textit{C57BL/6}~HF mouse retina may answer whether statins could work as a treatment for AMD.

\textbf{Conclusion}

AMD is a debilitating blindness with limited therapeutic options but there is hope of new treatments for this age-dependent retinal disease in the future. Over the years, implications of lipid metabolic dysregulation as a key pathological mechanism in AMD have emerged. We presented an overview of preclinical AMD mouse models that allow for the establishment of causative relationships with lipids and AMD-like pathology development. The use of these AMD mouse models may lead to worthy lipid-targeting candidate therapies for clinical trials to prevent the blindness caused by AMD.

\textbf{Acknowledgments}

The authors thank Dan Stamer, Mikael Klingeborn, and Daniel Grigsby for their intellectual feedback and advice.

\textbf{Author Disclosure Statement}

No competing financial interests exist.
References

1. Wong, W.L., Su, X., Li, X., Cheung, C.M., Klein, R., Cheng, C.Y., and Wong, T.Y. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. *Lancet Glob. Health.* 2.e106–e116, 2014.

2. Jager, R.D., Mieler, W.F., and Miller, J.W. Age-related macular degeneration. *N. Engl. J. Med.* 358:2606–2617, 2008.

3. Klein, R., Klein, B.E., and Linton, K.L. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. *Ophthalmology.* 99:933–943, 1992.

4. Vingerling, J.R., Dielemans, I., Grobbee, D.E., Hijmering, M., Kramer, C.F., and de Jong, P.T. The prevalence of age-related maculopathy in the Rotterdam Study. *Ophthalmology.* 102:205–210, 1995.

5. Miller, J.W. Age-related macular degeneration revisited—piecing the puzzle: the LXIX Edward Jackson memorial lecture. *Am. J. Ophthalmol.* 155:1–35, 2013.

6. Bowes Rickman, C., Farsiu, S., Toth, C.A., and Klingborn, M. Dry age-related macular degeneration: mechanisms, therapeutic targets, and imaging. *Invest. Ophthalmol. Vis. Sci.* 54:ORSF68–ORSF80, 2013.

7. Owsley, C., McGwin, G., Clark, M.E., Jackson, G.R., Callahan, M.A., Kline, L.B., Witherspoon, C.D., and Curcio, C.A. Delayed rod-mediated dark adaptation is a functional biomarker for incident early age-related macular degeneration. *Ophthalmology.* 123:344–351, 2016.

8. Ferris, F.L., Davis, M.D., Clemons, E.A., Lee, L.Y., Chew, E.Y., Lindblad, A.S., Milton, R.C., Bressler, S.B., Klein, R., and Age-Related Eye Disease Study Research Group. A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. *Arch. Ophthalmol.* 123:1570–1574, 2005.

9. Farazdagi, M.K., and Ebrahimi, K.B. Role of the choroid in age-related macular degeneration: a current review. *J. Ophthalmic Vis. Res.* 14:78–87, 2019.

10. Bonilha, V.L. Age and disease-related structural changes in the retinal pigment epithelium. *Clin. Ophthalmol.* 2:413–424, 2008.

11. Miller, J.W. Age-related macular degeneration revisited—piecing the puzzle: the LXIX Edward Jackson Memorial Lecture. *Am. J. Ophthalmol.* 155:48, 2013.

12. Yazdi, M.H., Faramarzi, M.A., Nikfar, S., Falavarjani, K.G., and Abdollahi, M. Ranibizumab and aflibercept for treating wet age-related macular degeneration: a systematic review and meta-analysis. *Drug Des. Devel. Ther.* 9:5397–5405, 2015.

13. Ba, J., Peng, R.S., Xu, D., Li, Y.H., Shi, H., Wang, Q., and Yu, J. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a comprehensive review. *Drug Des. Devel. Ther.* 10:1857–1867, 2016.

14. Gemenetzii, M., Lotery, A.J., and Patel, P.J. Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents. *Eye (Lond).* 31:1–9, 2017.

15. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. *Arch. Ophthalmol.* 119:1417–1436, 2001.

16. Aronow, M.E., and Chew, E.Y. Age-related eye disease study 2: perspectives, recommendations, and unanswered questions. *Curr. Opin. Ophthalmol.* 25:186–190, 2014.

17. Fritsche, L.G., Fariss, R.N., Stambolian, D., Abecasis, G.R., Curcio, C.A., and Swaroop, A. Age-related macular degeneration: genetics and biology coming together. *Annu. Rev. Genomics Hum. Genet.* 15:151–171, 2014.

18. Anderson, D.H., Radeke, M.J., Gallo, N.B., Chapin, E.A., Johnson, P.T., Curletti, C.R., Hancox, L.S., Hu, J., Ebright, J.N., Malek, G., Hauser, M.A., Rickman, C.B., Bok, D., Hageman, G.S., and Johnson, L.V. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. *Prog. Retin. Eye Res.* 29:95–112, 2010.

19. Landowski, M., Kelly, U., Klingborn, M., Groelle, M., Ding, J.D., Grigsby, D., and Bowes Rickman, C. Human complement factor H Y402H polymorphism causes an age-related macular degeneration phenotype and lipoprotein dysregulation in mice. *Proc. Natl. Acad. Sci. U. S. A.* 116:3703–3711, 2019.

20. Toomey, C.B., Kelly, U., Saban, D.R., and Bowes Rickman, C. Regulation of age-related macular degeneration-like pathology by complement factor H. *Proc. Natl. Acad. Sci. U. S. A.* 112:E3040–E3049, 2015.

21. Toomey, C.B., Johnson, L.V., and Bowes Rickman, C. Complement factor H in AMD: bridging genetic associations and pathobiology. *Prog. Retin. Eye Res.* 62:38–57, 2018.

22. Kelly, U.L., Grigsby, D., Cady, M.A., Landowski, M., Skiba, N.P., Liu, J., Remaley, A.T., Klingborn, M., and Bowes Rickman, C. High density lipoproteins are a potential therapeutic target for age-related macular degeneration. *J. Biol. Chem.* 295:13601–13616, 2020.

23. Piculella, I.A., and Curcio, C.A. Cholesterol in the retina: the best is yet to come. *Prog. Retin. Eye Res.* 41:64–89, 2014.

24. van Leeuwen, E.M., Emri, E., Merle, B.M.J., Colijn, J.M., Kersten, E., Cougnard-Gregoire, A., Dammeier, S., Hageman, G.S., and Lengyel, I. A new perspective on lipid research in age-related macular degeneration. *Prog. Retin. Eye Res.* 67:56–86, 2018.

25. Jun, S., Datta, S., Wang, L., Pegany, R., Cano, M., and Andha, J.T. The impact of lipids, lipid oxidation, and inflammation on AMD, and the potential role of miRNAs on lipid metabolism in the RPE. *Exp. Eye Res.* 181:346–355, 2019.
32. van Leeuwen, R., Klaver, C.C., Vingerling, J.R., Hofman, A., and de Jong, P.T. The risk and natural course of age-related maculopathy. *Arch. Ophthalmol.* 121:519–526, 2013.

33. Eells, J.T. Mitochondrial dysfunction in the aging retina. *Biology (Basel).* 8: 31, 2019.

34. Curcio, C.A., Johnson, M., Rudolf, M., and Huang, J.D. The oil spill in aging Bruch membrane. *Br. J. Ophthalmol.* 95:1638–1645, 2011.

35. Holz, F.G., Sheraidah, G., Pauleikhoff, D., and Bird, A.C. Analysis of lipid deposits extracted from human macular and peripheral Bruch’s membrane. *Arch. Ophthalmol.* 112:402–406, 1994.

36. Pauleikhoff, D., Harper, C.A., Marshall, J., and Bird, A.C. Aging changes in Bruch’s membrane. A histochemical and morphologic study. *Ophthalmology.* 97:171–178, 1990.

37. Anderson, D.H., Ozaki, S., Nealon, M., Neitz, J., Mullins, R.F., Hageman, G.S., and Johnson, L.V. Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: implications for the process of drusen formation. *Am. J. Ophthalmol.* 131: 767–781, 2001.

38. Mullins, R.F., Russell, S.R., Anderson, D.H., and Hageman, G.S. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. *FASEB J.* 14:835–846, 2000.

39. Wang, L., Clark, M.E., Crossman, D.K., Kojima, K., Messinger, J.D., Mobley, J.A., and Curcio, C.A. Abundant lipid and protein components of drusen. *PLoS One.* 5: e10329, 2010.

40. Li, C.M., Clark, M.E., Chimento, M.F., and Curcio, C.A. Apolipoprotein localization in isolated drusen and retinal apolipoprotein gene expression. *Invest. Ophthalmol. Vis. Sci.* 47:3119–3128, 2006.

41. Malek, G., Li, C.M., Guidry, C., Medeiros, N.E., and Curcio, C.A. Apolipoprotein B in cholesterol-containing drusen and basal deposits of human eyes with age-related maculopathy. *Am. J. Pathol.* 162:413–425, 2003.

42. Huang, Y., and Mahley, R.W. Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer’s diseases. *Neurobiol Dis.* 72 Pt A:3–12, 2014.
function and interaction with dietary factors. Ageing Res. Rev. 37:146–161, 2017.
59. Klaver, C.C., Kliffen, M., van Duijn, C.M., Hofman, A., Cruts, M., Grobbee, D.E., van Broeckhoven, C., and de Jong, P.T. Genetic association of apolipoprotein E with age-related macular degeneration. Am. J. Hum. Genet. 63: 200–206, 1998.
60. Schmidt, S., Saunders, A.M., De La Paz, M.A., Postel, E.A., Heinis, R.M., Agarwal, A., Scott, W.K., Gilbert, J.R., McDowell, J.G., Bazyk, A., Gass, J.D., Haines, J.L., and Pericak-Vance, M.A. Association of the apolipoprotein E gene with age-related macular degeneration: possible effect modification by family history, age, and gender. Mol. Vis. 6:287–293, 2000.
61. Zareparsi, S., Reddick, A.C., Branham, K.E., Moore, K.B., Jessup, L., Thoms, S., Smith-Wheelock, M., Yashar, B.M., and Swaroop, A. Association of apolipoprotein E alleles with susceptibility to age-related macular degeneration in a large cohort from a single center. Invest. Ophthalmol. Vis. Sci. 45:1306–1310, 2004.
62. McKay, G.J., Patterson, C.C., Chakravarthy, U., Dasari, S., Klaver, C.C., Vingerling, J.R., Ho, L., de Jong, P.T., Fletcher, A.E., Young, I.S., Seland, J.H., Rahu, M., Soubrane, G., Tomazzoli, L., Topouzis, F., Vioque, J., Hingorani, A.D., Sofat, R., Dean, M., Sawitzke, J., Seddon, J.M., Peter, I., Webster, A.R., Moore, A.T., Yates, J.R., Cipriani, V., Fritsche, L.G., Weber, B.H., Keilhauer, C.N., Lotery, A.J., Ennis, S., Klein, M.L., Francis, P.J., Stambolian, D., Orlin, A., Gorin, M.B., Weeks, D.E., Kuo, C.L., Swaroop, A., Othman, M., Kanda, A., Chen, W., Abecasis, G.R., Wright, A.F., Hayward, C., Baird, P.N., Guymier, R.H., Attia, J., Thakkinstian, A., and Silvestri, G. Evidence of association of APOE with age-related macular degeneration: a pooled analysis of 15 studies. Hum. Mutat. 32:1407–1416, 2011.
63. Chen, W., Stambolian, D., Edwards, A.O., Branham, K.E., Othman, M., Jakobsdottir, J., Tosakulwong, N., Pericak-Vance, M.A., Campochiaro, P.A., Klein, M.L., Tan, P.L., Conley, Y.P., Kanda, A., Kopplin, L., Li, Y., Augustatits, K.J., Karoukis, A.J., Scott, W.K., Agarwal, A., Kovach, J.J., Schwartz, S.G., Postel, E.A., Brooks, M., Baratz, K.H., Brown, W.L., Brucker, A.J., Orlin, A., Brown, G., Ho, A., Regillo, C., Donoso, L., Tian, L., Kaderli, B., Hadley, D., Hagstrom, S.A., Peachey, N.S., Klein, R., Klein, B.E., Gotoh, N., Yamashiro, K., Ferris Iii, F., Fageness, J.A., Reynolds, R., Farrer, L.A., Kim, I.K., Miller, J.W., Cortón, M., Carracedo, A., Sanchez-Salorio, M., Pugh, E.W., Doheny, K.F., Brion, M., Deangelis, M.M., Weeks, D.E., Zack, D.J., Chew, E.Y., Heckenlively, J.R., Yoshimura, N., Iyengar, S.K., Francis, P.J., Katsanis, N., Seddon, J.M., Haines, J.L., Gorin, M.B., Abecasis, G.R., Swaroop, A., and Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc. Natl. Acad. Sci. U. S. A. 107:7401–7406, 2010.
64. Neale, B.M., Fageness, J., Reynolds, R., Sobrin, L., Parker, M., Raychaudhuri, S., Tan, P.L., Oh, E.C., Merriam, J.E., Souied, E., Bernstein, P.S., Li, B., Frederick, J.M., Zhang, K., Brantley, M.A., Lee, A.Y., Zack, D.J., Campochiaro, B., Campochiaro, P., Ripke, S., Smith, R.T., Barile, G.R., Katsanis, N., Allikmets, R., Daly, M.J., and Seddon, J.M. Genome-wide association study of advanced age-related macular degeneration identifies a role
of the hepatic lipase gene (LIPC). *Proc. Natl. Acad. Sci. U. S. A.* 107:7395–7400, 2010.

65. Wang, Y.F., Han, Y., Zhang, R., Qin, L., Wang, M.X., and Ma, L. CETP/LPL/LIPC gene polymorphisms and susceptibility to age-related macular degeneration. *Sci. Rep.* 5:15711, 2015.

66. Storti, F., Klee, K., Todorova, V., Steiner, R., Othman, A., van der Velde-Visser, S., Samardzija, M., Meneau, I., Barben, M., Karademir, D., Pauzuolyte, V., Boye, S.L., Blaser, F., Ullmer, C., Dunaieff, J.L., Hornemann, T., Rohrer, L., den Hollander, A., von Eckardstein, A., Fingerle, J., Maugeais, C., and Grimm, C. Impaired ABCA1/ABCG1-mediated lipid efflux in the mouse retinal pigment epithelium (RPE) leads to retinal degeneration. *Elife.* 8: e45100, 2019.

67. Yvan-Charvet, L., Wang, N., and Tall, A.R. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. *Arterioscler. Thromb. Vasc. Biol.* 30:139–143, 2010.

68. Ersoy, L., Ristau, T., Lechanteur, Y.T., Hahn, M., Hoynig, C.B., Kirchhof, B., den Hollander, A.I., and Fauser, S. Nutritional risk factors for age-related macular degeneration. *Biomed. Res. Int.* 2014:43150, 2014.

69. Howard, K.P., Klein, B.E., Lee, K.E., and Klein, R. Measures of body shape and adiposity as related to incidence of age-related eye diseases: observations from the Beaver Dam Eye Study. *Invest. Ophthalmol. Vis. Sci.* 55: 2592–2598, 2014.

70. Ersoy, L., Ristau, T., Hahn, M., Karlstetter, M., Langmann, T., Droge, K., Caramoy, A., den Hollander, A.I., and Fauser, S. Genetic and environmental risk factors for age-related macular degeneration in persons 90 years and older. *Invest. Ophthalmol. Vis. Sci.* 55:1842–1847, 2014.

71. Smith, W., Mitchell, P., and Leeder, S.R. Smoking and age-related maculopathy. The Blue Mountains Eye Study. *Arch. Ophthalmol.* 114:1518–1523, 1996.

72. Vingerling, J.R., Hofman, A., Grobbee, D.E., and de Jong, P.T. Age-related macular degeneration and smoking. The Rotterdam Study. *Arch. Ophthalmol.* 114:1193–1196, 1996.

73. Armstrong, R.A., and Mousavi, M. Overview of risk factors for age-related macular degeneration (AMD). *J. Stem Cells.* 10:171–191, 2015.

74. Clemons, T.E., Milton, R.C., Klein, R., Seddon, J.M., and Ferris, F.L., 3rd. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. *Ophthalmology.* 112:533–539, 2005.

75. Heibia, I.M., Elston, R.C., Klein, B.E., and Klein, R. Sibling correlations and segregation analysis of age-related maculopathy: the Beaver Dam Eye Study. *Genet. Epidemiol.* 11:51–67, 1994.

76. Vingerling, J.R., Klaver, C.C., Hofman, A., and de Jong, P.T. Epidemiology of age-related maculopathy. *Epidemiol. Rev.* 17:347–360, 1995.

77. Fujihara, M., Bartels, E., Nielsen, L.B., and Handa, J.T. A human apoB100 transgenic mouse expresses human apoB100 in the RPE and develops features of early AMD. *Exp. Eye Res.* 88:1115–1123, 2009.

78. Ong, J.M., Zorapel, N.C., Rich, K.A., Wagstaff, R.E., Lambert, R.W., Rosenberg, S.E., Moghaddas, F., Pirouzmannesh, A., Aoki, A.M., and Kenney, M.C. Effects of cholesterol and apolipoprotein E on retinal abnormalities in ApoE-deficient mice. *Invest. Ophthalmol. Vis. Sci.* 42: 1891–1900, 2001.

79. Saadane, A., Petrov, A., Mast, N., El-Darzi, N., Dao, T., Alnemri, A., Song, Y., Dunaief, J.L., and Pikuleva, I.A. Mechanisms that minimize retinal impact of apolipoprotein E absence. *J. Lipid Res.* 59:2368–2382, 2018.

80. Malek, G., Johnson, L.V., Mace, B.E., Saloupies, P., Schmechel, D.E., Rickman, D.W., Toth, C.A., Sullivan, P.M., and Bowes Rickman, C. Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration. *Proc. Natl. Acad. Sci. U. S. A.* 102:11900–11905, 2005.

81. Ding, J.D., Johnson, L.V., Herrmann, R., Farsiu, S., Smith, S.G., Groelle, M., Mace, B.E., Sullivan, P., Jamison, J.A., Kelly, U., Harrabi, O., Bollini, S.S., Dilley, J., Kobayashi, D., Kuang, B., Li, W., Pons, J., Lin, J.C., and Bowes Rickman, C. Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. *Proc. Natl. Acad. Sci. U. S. A.* 108:E279–E287, 2011.

82. Barathi, V.A., Yeo, S.W., Guymer, R.H., Wong, T.Y., and Loo, C.D. Effects of simvastatin on retinal structure and function of a high-fat atherogenic mouse model of thickened Bruch’s membrane. *Invest. Ophthalmol. Vis. Sci.* 55: 460–468, 2014.

83. Zhao, Z., Xu, P., Jie, Z., Zuo, Y., Yu, B., Soong, L., Sun, J., Chen, Y., and Cai, J. Gamma delta T cells as a major source of IL-17 production during age-dependent RPE degeneration. *Invest. Ophthalmol. Vis. Sci.* 55:6580–6589, 2014.

84. Zhang, M., Chu, Y., Mowery, J., Konkel, B., Galli, S., Theos, A.C., and Golestanineh, N. Pgc-1α repression and high-fat diet induce age-related macular degeneration-like phenotypes in mice. *Dis. Model. Mech.* 11: dmm032698, 2018.

85. Cho, E., Hung, S., Willett, W.C., Spiegelman, D., Rimm, E.B., Seddon, J.M., Colditz, G.A., and Hankinson, S.E. Prospective study of dietary fat and the risk of age-related macular degeneration. *Am. J. Clin. Nutr.* 73:209–218, 2001.

86. Seddon, J.M., Rosner, B., Sperduto, R.D., Yannuzzi, L., Haller, J.A., Blair, N.P., and Willett, W. Dietary fat and risk for advanced age-related macular degeneration. *Arch. Ophthalmol.* 119:1191–1199, 2001.

87. Seddon, J.M., Cote, J., and Rosner, B. Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake. *Arch. Ophthalmol.* 121:1728–1737, 2003.

88. Seddon, J.M., George, S., and Rosner, B. Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: the US Twin Study of Age-Related Macular Degeneration. *Arch. Ophthalmol.* 124:995–1001, 2006.

89. Yiu, G., Tieu, E., Munever, C., Wong, B., Cunefare, D., Farsiu, S., Garzel, L., Roberts, J., and Thomasy, S.M. In vivo multimodal imaging of drusenoid lesions in rhesus macaque. *Sci. Rep.* 7:15013, 2017.

90. Francis, P.J., Appukuttan, B., Simmons, E., Landauer, N., Stoddard, J., Hamon, S., Ott, J., Ferguson, B., Klein, M., Stout, J.T., and Neuringer, M. Rhesus monkeys and humans share common susceptibility genes for age-related macular disease. *Hum. Mol. Genet.* 17:2673–2680, 2008.

91. Gestri, G., Link, B.A., and Neuhauss, S.C. The visual system of zebrafish and its use to model human ocular diseases. *Dev. Neurobiol.* 72:302–327, 2012.

92. Chhetri, J., Jacobson, G., and Gueven, N. Zebrafish—on the move towards ophthalmological research. *Eye (Lond).* 28:367–380, 2014.
TARGETING LIPID METABOLISM FOR THE TREATMENT OF AMD

93. Kolesnikov, A.V., Fan, J., Crouch, R.K., and Kefalov, V.J. Age-related deterioration of rod vision in mice. *J. Neurosci*. 30:11222–11231, 2010.

94. Williams, G.A., and Jacobs, G.H. Cone-based vision in the aging mouse. *Vision Res.* 47:2037–2046, 2007.

95. Mori, H., Yamada, H., Toyama, K., Takahashi, K., Akama, T., Inoue, T., and Nakamura, T. Developmental and age-related changes to the elastic lamina of Bruch’s membrane in mice. *Graefes Arch. Clin. Exp. Ophthalmol.* 257:289–301, 2019.

96. Chen, M., Rajapakse, D., Fraczek, M., Luo, C., Forrester, J.V., and Xu, H. Retinal pigment epithelial cell multinucleation in the aging eye—a mechanism to repair damage and maintain homeostasis. *Aging Cell.* 15:436–445, 2016.

97. Wolf, N.S., Li, Y., Pendergrass, W., Schneider, C., and Turturro, A. Normal mouse and rat strains as models for age-related cataract and the effect of caloric restriction on its development. *Exp. Eye Res.* 70:683–692, 2000.

98. Higuchi, H., Macke, E.L., Lee, W.H., Miller, S.A., Xu, J.C., Ikeda, S., and Ikeda, A. Genetic basis of age-dependent synaptic abnormalities in the retina. *Mamm. Genome*. 26:21–32, 2015.

99. Xu, H., Chen, M., Manivannan, A., Lois, N., and Forrester, J.V. Age-dependent accumulation of lipofuscin in perivascular and subretinal microglia in experimental mice. *Aging Cell.* 7:58–68, 2008.

100. Choudhary, M., Ismail, E.N., Yao, P.L., Tayyari, F., Radu, R.A., Nusinowitz, S., Boulton, M.E., Apte, R.S., Ruberti, J.W.; Handa, J.T., Tontonoz, P., and Malek, G. LXR ligands regulate features of age-related macular degeneration and may be a potential therapeutic target. *JCI Insight*. 5: e131928, 2020.

101. Fujihara, M., Cano, M., and Handa, J.T. Mice that produce Hu, P., Herrmann, R., Bednar, A., Saloupis, P., Dwyer, H., Macke, E.L., Lee, W.H., Miller, S.A., Xu, H., Chen, M., Manivannan, A., Lois, N., and Forrester, J.V. Age-dependent accumulation of lipofuscin in perivascular and subretinal microglia in experimental mice. *Aging Cell.* 7:58–68, 2008.

102. Ding, J.D., Kelly, U., Landowski, M., Toomey, C.B., Groelle, M., Miller, C., Smith, S.G., Klingeborn, M., Singhapricha, T., Jiang, H., Frank, M.M., and Bowes Rickman, C. Expression of human complement factor H prevents age-related macular degeneration-like retina damage and kidney abnormalities in aged cfh knockout mice. *Am. J. Pathol.* 185:29–42, 2015.

103. Lennikov, A., Saddala, M.S., Mukwaya, A., Tang, S., and Huang, H. Autoimmune-mediated retinopathy in CXCR5-deficient mice as the result of age-related macular degeneration associated proteins accumulation. *Front. Immunol.* 10:1903, 2019.

104. Notomi, S., Ishihara, K., Efstathiou, N.E., Lee, J.J., Hitosomi, T., Tachibana, T., Konstantinou, E.K., Ueta, T., Murakami, Y., Maidana, D.E., Ikeda, Y., Kume, S., Terasaki, H., Sonoda, S., Blanz, J., Young, L., Sakamoto, T., Sonoda, K.H., Saitog, P., Ishihashi, T., Miller, J.W., Kroemer, G., and Vavvas, D.G. Genetic LAMP2 deficiency accelerates the age-associated formation of basal laminar deposits in the retina. *Proc. Natl. Acad. Sci. U. S. A.* 116:23724–23734, 2019.

105. Hashizume, K., Hirasa, M., Imamura, Y., Noda, S., Shimizu, T., Shinoda, K., Kurihara, T., Noda, K., Ozawa, Y., Ishida, S., Miyake, Y., Shirasawa, T., and Tsubota, K. Retinal dysfunction and progressive retinal cell death in SOD1-deficient mice. *Am. J. Pathol.* 172:1325–1331, 2008.

106. Imamura, Y., Noda, S., Hashizume, K., Shinoda, K., Yamaguchi, M., Uchiyama, S., Shimizu, T., Mizushima, Y., Shirasawa, T., and Tsubota, K. Drusen, choroidal neovascularization, and retinal pigment epithelium dysfunction in SOD1-deficient mice: a model of age-related macular degeneration. *Proc. Natl. Acad. Sci. U. S. A.* 103: 11282–11287, 2006.
117. Justilien, Y., Pang, J.J., Renganathan, K., Zhan, X., Crabb, J.W., Kim, S.R., Sparrow, J.R., Hauswirth, W.W., and Lewin, A.S. SOD2 knockout mouse model of early AMD. *Invest. Ophthalmol. Vis. Sci.* 48:4407–4420, 2007.

118. Mao, H., Seo, S.I., Biswal, M.R., Li, H., Conners, M., Nandyala, A., Jones, K., Le, Y.Z., and Lewin, A.S. Mitochondrial oxidative stress in the retinal pigment epithelium leads to localized retinal degeneration. *Invest. Ophthalmol. Vis. Sci.* 55:4613–4627, 2014.

119. Nakayama, M., Iejima, D., Akahori, M., Kamei, J., Goto, A., and Iwata, T. Overexpression of Htra1 and exposure to mainstream cigarette smoke leads to choroidal neo-vascularization and subretinal deposits in aged mice. *Invest. Ophthalmol. Vis. Sci.* 55:6514–6523, 2014.

120. Wright, C.B., Uehara, H., Kim, Y., Yasuama, T., Yasuma, R., Hirahara, S., Makin, R.D., Apicella, I., Pereira, F., Nagasaka, Y., Narendran, S., Fukuda, S., Albuquerque, R., Fowler, B.J., Bastos-Carvalho, A., Georgel, P., Hatada, I., Chang, B., Kerur, N., Ambati, B.K., Ambati, J., and Gelfand, B.D. Chronic Dicer1 deficiency promotes atrophy and neovascular outer retinal pathologies in mice. *Proc. Natl. Acad. Sci. U. S. A.* 117:2579–2587, 2020.

121. Landowski, M., Grindel, S., Shahi, P.K., Johnson, A., Western, D., Race, A., Shi, F., Benson, J., Gao, M., Santoorire, E., Lee, W.H., Ikeda, S., Pattnaik, B.R., and Ikeda, A. Modulation of Tmem135 leads to retinal pigment epithelium pathologies in mice. *Invest. Ophthalmol. Vis. Sci.* 61:16, 2020.

122. Cheng, S.Y., Cipi, J., Ma, S., Hafler, B.P., Kanadia, R.N., Brush, R.S., Agbagla, M.P., and Punzo, C. Altered photoreceptor metabolism in mouse causes late stage age-related macular degeneration-like pathologies. *Proc. Natl. Acad. Sci. U. S. A.* 117:13094–13104, 2020.

123. Choudhary, M., Ding, J.D., Qi, X., Boulton, M.E., Yao, P.L., Peters, J.M., and Malek, G. PPARβ/δ selectively regulates phenotypic features of age-related macular degeneration. *Aging (Albany NY).* 8:1952–1978, 2016.

124. Lyzogubov, V.V., Bora, P.S., Wu, X., Horn, L.E., de Roque, R., Rudolf, X.V., Atkinson, J.P., and Bora, N.S. The complement regulatory protein CD46 deficient mouse spontaneously develops dry-type age-related macular degeneration-like phenotype. *Am. J. Pathol.* 186:2088–2104, 2016.

125. Franco, L.M., Zulliger, R., Wolf-Schnurrbusch, U.E., Katagiri, Y., Kaplan, H.J., Wolf, S., and Enzmann, V. Decreased visual function after patchy loss of retinal pigment epithelium induced by low-dose sodium iodate. *Invest. Ophthalmol. Vis. Sci.* 50:4004–4010, 2009.

126. Enzmann, V., Row, B.W., Yamauchi, Y., Kheirandish, L., Gozal, D., Kaplan, H.J., and McCall, M.A. Behavioral and anatomical abnormalities in a sodium iodate-induced model of retinal pigment epithelium degeneration. *Exp. Eye Res.* 82:441–448, 2006.

127. Lambert, V., Lecomte, J., Hansen, S., Blacher, S., Gonzalez, M.L., Struman, I., Soumi, N.E., Rozet, E., de Tullio, P., Foidart, J.M., Rakic, J.M., and Noel, A. Laser-induced choroidal neoangiogenesis model to study age-related macular degeneration in mice. *Nat. Protoc.* 8: 2197–2211, 2013.

128. Jones, A., Kumar, S., Zhang, N., Tong, Z., Yang, J.H., Watt, C., Anderson, J., Amrita, Fillerup, H., McCloskey, M., Luo, L., Yang, Z., Ambati, B., Marc, R., Oka, C., Zhang, K., and Fu, Y. Increased expression of multifunctional serine protease, HTRA1, in retinal pigment epithelium induces polyoidal choroidal vasculopathy in mice. *Proc. Natl. Acad. Sci. U. S. A.* 108:14578–14583, 2011.

129. Vierkotten, S., Muether, P.S., and Fauser, S. Overexpression of HTRA1 leads to ultrastructural changes in the elastic layer of Bruch’s membrane via cleavage of extracellular matrix components. *PLoS One.* 6:e22959, 2011.

130. Williams, B.L., Seager, N.A., Gardiner, J.D., Pappas, C.M., Cronin, M.C., Amat di San Filippo, C., Anstadt, R.A., Liu, J., Tosso, M.A., Nichols, L., Parnell, T.J., Eve, J.R., Bartel, P.L., Zouache, M.A., Richards, B.T., and Hageman, G.S. Chromosome 10q26-driven age-related macular degeneration is associated with reduced levels of HTRA1 in human retinal pigment epithelium. *Proc. Natl. Acad. Sci. U. S. A.* 118:e2103617118, 2021.

131. Wu, B.X., Fan, J., Boyer, N.P., Jenkins, R.W., Koutalos, Y., Hannun, Y.A., and Crosson, C.E. Lack of acid sphingomyelinase induces age-related retinal degeneration. *PLoS One.* 10:e0133032, 2015.

132. Fujihara, M., Nagai, N., Sussan, T.E., Biswal, S., and Handa, J.T. Chronic cigarette smoke causes oxidative damage and apoptosis to retinal pigment epithelial cells in mice. *PLoS One.* 3:e3119, 2008.

133. Doyle, S.L., Campbell, M., Ozaki, E., Salomon, R.G., Mori, A., Kenna, P.F., Farrar, G.J., Kiang, A.S., Humphries, M.M., Lavelle, E.C., O’Neill, L.A., Hollifield, J.G., and Humphries, P. NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. *Nat. Med.* 18:791–798, 2012.

134. Cruz-Guilloty, F., Saeed, A.M., Eccegaray, J.J., Duffort, S., Ballmick, A., Tan, Y., Betancourt, M., Viteri, E., Ramkhellawon, G.C., Ewald, E., Feuer, W., Huang, D., Wen, R., Hong, L., Wang, H., Laird, J.M., Sene, A., Apte, R.S., Salomon, R.G., Hollifield, J.G., and Perez, V.L. Infiltration of proinflammatory m1 macrophages into the outer retina precedes damage in a mouse model of age-related macular degeneration. *Int. J. Inflamm.* 2013:503725, 2013.

135. Schnabolk, G., Obert, E., Banda, N.K., and Rohrer, B. Systemic inflammation by collagen-induced arthritis affects the progression of age-related macular degeneration differently in two mouse models of the disease. *Invest. Ophthalmol. Vis. Sci.* 61:11, 2020.

136. Hadziahmetovic, M., Song, Y., Wolkow, N., Iacovelli, J., Gregio, S., Lee, J., Lyubarsky, A., Pratico, D., Connelly, J., Spino, M., Harris, Z.L., and Duniaef, J.L. The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration. *Invest. Ophthalmol. Vis. Sci.* 52:959–968, 2011.

137. Lundh von Leithner, P., Kam, J.H., Bainbridge, J., Catchpole, I., Gough, G., Coffey, P., and Jeffery, G. Complement factor h is critical in the maintenance of retinal perfusion. *Am. J. Pathol.* 175:412–421, 2009.

138. Toomey, C.B., Landowski, M., Klingeborn, M., Kelly, U., Deans, J., Dong, H., Harrabi, O., Van Blarcom, T., Yeung, Y.A., Grishanin, R., Lin, J.C., Saban, D.R., and Bowes Rickman, C. Effect of anti-C5a therapy in a murine model of early/intermediate dry age-related macular degeneration. *Invest. Ophthalmol. Vis. Sci.* 59:662–673, 2018.

139. Lesher, A.M., Zhou, L., Kimura, Y., Sato, S., Gullipalli, D., Herbert, A.P., Barlow, P.N., Eberhardt, H.U., Skerka, C., Zipfel, P.F., Hamano, T., Miwa, T., Tung, K.S., and Song, W.C. Combination of factor H mutation and pro-inflammatory NLRP3 inflammasome components interacts selectively with drusen components. *Nat. Med.* 18:791–798, 2012.

140. Handa, J.T., Kaplan, H.J., Barlow, P.N., Eberhardt, H.U., Skerka, C., Zipfel, P.F., Hamano, T., Miwa, T., Tung, K.S., and Song, W.C. Combination of factor H mutation and pro-inflammatory NLRP3 inflammasome components interacts selectively with drusen components. *Nat. Med.* 18:791–798, 2012.
TARGETING LIPID METABOLISM FOR THE TREATMENT OF AMD

140. Song, D., Mohammed, I., Bhuyan, R., Miwa, T., Williams, A.L., Gallipalli, D., Sato, S., Song, Y., Dunaief, J.L., and Song, W.C. Retinal basal laminar deposits in complement FH/IP mouse model of dense deposit disease. Invest. Ophthalmol. Vis. Sci. 59:3405–3415, 2018.

141. Huang, H., and Lennikov, A. CXCR5/NRF2 double knockout mice develop retinal degeneration phenotype at early adult age. Exp. Eye Res. 196:108061, 2020.

142. Dhillon, A., Bell, B.A., Peachey, N.S., Daniele, L.L., Reyes-Reveles, J., Sharp, R.C., Jun, B., Bazan, N.G., Sparrow, J.R., Kim, H.J., Philip, N.J., and Boesze-Battaglia, K. Microtubule-associated protein 1 light chain 3B, (LC3B) is necessary to maintain lipid-mediated homeostasis in the retinal pigment epithelium. Front. Cell Neurosci. 12:351, 2018.

143. Felszeghy, S., Viiri, J., Paterno, J.J., Hyytinen, J.M.T., Koskela, A., Chen, M., Leinonen, H., Tanila, H., Kivinen, N., Koistinen, A., Toropainen, E., Amadio, M., Smedowski, A., Reinisalo, M.,WINIARZYK, M., MACKIEWICK, J., Mutikainen, M., Ruotsalainen, A.K., Kettunen, M., Jokivari, K., Sinha, D., Kinnunen, K., Petrovski, G., Blasiak, J., Björklund, G., Koskelainen, A., Skottum, H., Urtti, A., Salminen, A., Kannan, R., Ferrington, D.A., Xu, H., Levonen, A.L., Tavi, P., Kauppinnen, A., and Kaariranta, K. Loss of NRF-2 and PGC-1α genes leads to retinal pigment epithelium damage resembling dry age-related macular degeneration. Redox Biol. 20:1–12, 2019.

144. Yao, J., Jia, L., Khan, N., Lin, C., Mitter, S.K., Boulton, M.E., Dunaief, J.L., Klionksy, D.J., Guan, J.L., Thompson, D.A., and Zacks, D.N. Deletion of autophagy inducer RB1CC1 results in degeneration of the retinal pigment epithelium. Autophagy. 11:939–953, 2015.

145. Dong, A., Shen, J., Krause, M., Akiyama, H., Hackett, S.F., Lai, H., and Campochiaro, P.A. Superoxide dismutase 1 protects retinal cells from oxidative damage. J. Cell. Physiol. 208:516–526, 2006.

146. Qi, X., Pay, S.L., Yan, Y., Thomas, J., Jr., Lewin, A.S., Chang, L.J., Grant, M.B., and Boulton, M.E. Systemic injection of RPE65-programmed bone marrow-derived cells prevents progression of chronic retinal degeneration. Mol. Ther. 25:917–927, 2017.

147. Choudhary, M., Kazmin, D., Hu, P., Thomas, R.S., McDonnell, D.P., and Malek, G. Aryl hydrocarbon receptor knock-out exacerbates choroidal neovascularization via multiple pathogenic pathways. J. Pathol. 235:101–112, 2015.

148. Combadiere, C., Feumi, C., Raoul, W., Keller, N., Dero, M., Pesard, A., Lavallette, S., Houssier, M., Jonet, L., Picard, E., Debre, P., Sirinyan, M., Deterre, P., Ferroukhi, T., Cohen, S.Y., Chauvaud, D., Jeanny, J.C., Cachafeiro, M., Bemelmans, A.P., Samardzija, M., Afa- nasieva, T., Pournaras, J.A., Grimm, C., Kostic, C., Philippe, S., Wenzel, A., and Arsenijevic, Y. Hyperactivation of retina by light in mice leads to photoreceptor cell death mediated by VEGF and retinal pigment epithelium permeability. Cell Death Dis. 4:e781, 2013.

149. Krzyzstolik, M.G., Afshari, M.A., Adamis, A.P., Gaudreau, J., Gragoudas, E.S., Michaud, N.A., Li, W., Connolly, E., O’Neill, C.A., and Miller, J.W. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthalmol. 120:338–346, 2002.

150. Lyzogubov, V.V., Tytarenko, R.G., Liu, J., Bora, N.S., and Bora, P.S. Polyethylene glycol (PEG)-induced mouse model of choroidal neovascularization. J. Biol. Chem. 286:16229–16237, 2011.

151. Li, C., Huang, Z., Kingsley, R., Zhou, X., Li, F., Parke, D.W., and Cao, W. Biochemical alterations in the retinas of very low-density lipoprotein receptor knockout mice: an animal model of retinal angiomatic proliferation. Arch. Ophthalmol. 125:795–803, 2007.

152. Tarallo, V., Hirano, Y., Gelfand, B.D., Dridi, S., Kerur, N., Kim, Y., Cho, W.G., Kaneko, H., Fowler, B.J., Bogdanovich, S., Albuquerque, R.J., Hauswirth, W.W., Chiodo, V.A., Kugel, J.F., Goodrich, J.A., Ponicsan, S.L., Chaudhuri, G., Murphy, M.P., Dunaief, J.L., Ambati, B.K., Oguna, Y., Yoo, J.W., Lee, D.K., Provost, P., Hinton, D.R., Nunez, G., Baffi, J.Z., Kleinman, M.E., and Ambati, J. DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell. 149:847–859, 2012.

153. Kaneko, H., Dridi, S., Tarallo, V., Gelfand, B.D., Fowler, B.J., Cho, W.G., Kleinman, M.E., Ponicsan, S.L., Hauswirth, W.W., Chiodo, V.A., Gariko, K., Yoo, J.W., Lee, D.K., Hadziahmetovic, M., Song, Y., Misra, S., Chaudhuri, G., Buas, F.W., Braun, R.E., Hinton, D.R., Zhang, Q., Grossniklaus, H.E., Provis, J.M., Madigan, M.C., Milam, A.H., Justice, N.L., Albuquerque, R.J., Blandford, A.D., Bogdanovich, S., Hiran, Y., Witta, J., Fuchs, E., Littman, D.R., Ambati, B.K., Rudin, C.M., Chong, M.M., Provost, P., Kugel, J.F., Goodrich, J.A., Dunaief, J.L., Baffi, J.Z., and Ambati, J. DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature. 471:325–330, 2011.

154. Longbottom, R., Fruttiger, M., Douglas, R.H., Martinez-Barbera, J.P., Greenwood, J., and Moss, S.E. Genetic ablation of retinal pigment epithelial cells reveals the adaptive response of the epithelium and impact on photoreceptors. Proc. Natl. Acad. Sci. U. S. A. 106:18728–18733, 2009.

155. Chowers, G., Cohen, M., Marks-Ohana, D., Stika, S., Eijzenberg, A., Banin, E., and Obolensky, A. Course of sodium iodate-induced retinal degeneration in albino and pigmented mice. Invest. Ophthalmol. Vis. Sci. 58:2239– 2249, 2017.

156. Ibbott, P., Goverdhan, S.V., Pipi, E., Chouhan, J.K., Keeling, E., Angus, E.M., Scott, J.A., Gatherer, M., Page, A., Teeling, J.L., and Arjuna Ratnayaka, J. A lasered mouse model of retinal degeneration displays progressive outer retinal pathology providing insights into early geographic atrophy. Sci. Rep. 9:7475, 2019.

157. O’Koren, E.G., Mathew, R., and Saban, D.R. Fate mapping reveals that microglia and recruited monocye-derived macrophages are definitively distinguishable by phenotype in the retina. Sci. Rep. 6:20636, 2016.

158. Cachafeiro, M., Bemelmans, A.P., Samardzija, M., Afasasieva, T., Pournaras, J.A., Grimm, C., Kostic, C., Philippe, S., Wenzel, A., and Arsenijevic, Y. Hyperactivation of retina by light in mice leads to photoreceptor cell death mediated by VEGF and retinal pigment epithelium permeability. Cell Death Dis. 4:e781, 2013.

159. Chen, L., Wu, W., Dentchev, T., Zeng, Y., Wang, J., Tsui, I., Tobias, J.W., Bennett, J., Baldwin, D., and Dunaief, J.L. Light damage induced changes in mouse retinal gene expression. Exp. Eye Res. 79:239–247, 2004.

160. Grimm, C., and Reme, C.E. Light damage as a model of retinal degeneration. Methods Mol. Biol. 935:87–97, 2013.

161. Cingolani, C., Rogers, B., Lu, L., Kachi, S., Shen, J., and Campochiaro, P.A. Retinal degeneration from oxidative damage. Free Radic. Biol. Med. 40:660–669, 2006.
162. Espinosa-Heidmann, D.G., Suner, I.J., Catanuto, P., Hernandez, E.P., Marin-Castano, M.E., and Cousins, S.W. Cigarette smoke-related oxidants and the development of sub-RPE deposits in an experimental animal model of dry AMD. Invest. Ophthalmol. Vis. Sci. 47:729–737, 2006.

163. Montalbán-Soler, L., Alarcon-Martinez, L., Jimenez-Lopez, M., Salinas-Navarro, M., Galindo-Romero, C., Bezerra de Sá, F., García-Ayuso, D., Avilés-Trigueros, M., Vidal-Sanz, M., Agudo-Barriuso, M., and Villegas-Pérez, M.P. Retinal compensatory changes after light damage in albino mice. Mol. Vis. 18:675–693, 2012.

164. Radu, R.A., Hu, J., Yuan, Q., Welch, D.L., Makshanoff, J., Lloyd, M., McMullen, S., Travis, G.H., and Bok, D. Complement system dysregulation and inflammation in the retinal pigment epithelium of a mouse model for Stargardt macular degeneration. J. Biol. Chem. 286:18593–18601, 2011.

165. Chen, Y., Palczewska, G., Mustafi, D., Golczak, M., Dong, Z., Sawada, O., Maeda, T., Maeda, A., and Palczewski, K. Systems pharmacology identifies drug targets for Stargardt disease-associated retinal degeneration. J. Clin. Investig. 123:5119–5134, 2013.

166. Weng, J., Mata, N.L., Azarian, S.M., Tzekov, R.T., Birch, D.G., and Travis, G.H. Insights into the function of Rim protein in photoreceptors and etiology of Stargard’s disease from the phenotype in abcr knockout mice. Cell. 98:13–23, 1999.

167. Charbel Issa, P., Barnard, A.R., Singh, M.S., Carter, E., Jiang, Z., Radu, R.A., Schraermeyer, U., and MacLaren, R.E. Fundus autofluorescence in the Abca4(−/−) mouse model of Stargardt disease—correlation with accumulation of A2E, retinal function, and histology. Invest. Ophthalmol. Vis. Sci. 54:S602–S612, 2013.

168. Chavali, V.R., Khan, N.W., Cukras, C.A., Bartsch, D.U., Chavali, V.R., Khan, N.W., Cukras, C.A., Bartsch, D.U., and Pierce, E.A. DHRD/ML, an inherited macular degeneration. Mol. Genet. Hum. Genet. 16:2411–2422, 2007.

169. Marmorstein, L.Y., McLaughlin, P.J., Peache, N.S., Sasaki, T., and Marmorstein, A.D. Formation and progression of sub-retinal pigment epithelium deposits in Efemp1 mutation knock-in mice: a model for the early pathogenic course of macular degeneration. Hum. Mol. Genet. 16:2423–2432, 2007.

170. Mandal, N.A., Tran, J.T., Zheng, L., Wilkerson, J.L., Brush, R.S., McRae, J., Agbaga, M.P., Zhang, K., Petrukhin, K., Ayyagari, R., and Anderson, R.E. In vivo effect of mutant ELOVL4 on the expression and function of wild-type ELOVL4. Invest. Ophthalmol. Vis. Sci. 55:2705–2713, 2014.

171. Karan, G., Lillo, C., Yang, Z., Cameron, D.J., Locke, K.G., Zhao, Y., Thirumalaiyach, S., Li, C., Birch, D.G., Vollmer-Snarr, H.R., Williams, D.S., and Zhang, K. Lipofuscin accumulation, abnormal electrophysiology, and photoreceptor degeneration in mutant ELOVL4 transgenic mice: a model for macular degeneration. Proc. Natl. Acad. Sci. U. S. A. 102:4164–4169, 2005.

172. Vasireddy, V., Jablonski, M.M., Mandal, M.N., Raz-Prag, D., Wang, X.F., Nizol, L., Iannaccone, A., Musch, D.C., Bush, R.A., Salem, N., Jr., Sieving, P.A., and Ayyagari, R. Elovl4 5-bp-deletion knock-in mice develop progressive photoreceptor degeneration. Invest. Ophthalmol. Vis. Sci. 47:4558–4568, 2006.

173. Qi, J.H., Dai, G., Luthert, P., Chaurasia, S., Hollyfield, J., Weber, B.H., Stohr, H., and Anand-Apte, B. S156C mutation in tissue inhibitor of metalloproteinases-3 induces increased angiogenesis. J. Biol. Chem. 284:19927–19936, 2009.

174. Weber, B.H., Lin, B., White, K., Kohler, K., Soboleva, G., Herterich, S., Seeberger, M. W., Jaisle, G. B., Grimm, C., Reme, C., Wenzel, A., Asan, E., and Schrewe, H. A mouse model for Sorsby fundus dystrophy. Invest. Ophthalmol. Vis. Sci. 43:2732–2740, 2002.

175. Grossniklaus, H.E., Kang, S.J., and Berglin, L. Animal models of choroidal and retinal neovascularization. Prog. Retin. Eye Res. 29:500–519, 2010.

176. Poor, S.H., Qiu, Y., Fassbender, E.S., Shen, S., Woolfenden, A., Delpero, A., Kim, Y., Buchanan, N., Gebühr, T.C., Hanks, S.M., Meredith, E.L., Jaffée, B.D., and Dryja, T.P. Reliability of the mouse model of choroidal neovascularization induced by laser photocogulation. Invest. Ophthalmol. Vis. Sci. 55:6525–6534, 2014.

177. Yanai, R., Mulki, L., Hasegawa, E., Takeuchi, K., Swei-gard, H., Suzuki, J., Gaisert, P., Vavvas, D.G., Sonoda, K.H., Rothe, M., Schunck, W.H., Miller, J.W., and Connor, K.M. Cytochrome P450-generated metabolites derived from ω-3 fatty acids attenuate neovascularization. Proc. Natl. Acad. Sci. U. S. A. 111:9603–9608, 2014.

178. Yanai, R., Chen, S., Uchi, S.H., Narmi, T., Connor, K.M., and Kimura, K. Attenuation of choroidal neovascularization by dietary intake of ω-3 long-chain polyunsaturated fatty acids and lutein in mice. Proc. Natl. Acad. Sci. U. S. A. 111:9603–9608, 2014.

179. Fu, Z., Liegl, R., Wang, Z., Gong, Y., Liu, C.H., Sun, Y., Cakir, B., Burnim, S.B., Meng, S.S., Lüfqivist, C., San-Giovanni, J.P., Hellström, A., and Smith, L.E.H. Adiponectin mediates dietary omega-3 long-chain polyunsaturated fatty acid protection against choroidal neovascularization in mice. Invest. Ophthalmol. Vis. Sci. 58:3862–3870, 2017.

180. Koto, T., Nagai, N., Mochimarhu, H., Kurihara, T., Izumi-Nagai, K., Satofuka, S., Shinoda, H., Noda, K., Ozawa, Y., Inoue, M., Tsubota, K., Oike, Y., and Ishida, S. Eicosapentaenoic acid is anti-inflammatory in preventing choroidal neovascularization in mice. Invest. Ophthalmol. Vis. Sci. 48:4328–4334, 2007.

181. Zhu, L., Parker, M., Enemchukwu, N., Shen, M., Zhang, G., Yan, Q., Handsa, J.T., Fang, L., and Fu, Y. Combination of apolipoprotein-A-I/apolipoprotein-A-I binding protein and anti-VEGF treatment overcomes anti-VEGF resistance in choroidal neovascularization in mice. Commun. Biol. 3:386, 2020.
TARGETING LIPID METABOLISM FOR THE TREATMENT OF AMD

186. Terao, R., Honjo, M., and Aihara, M. Apolipoprotein M inhibits angiogenic and inflammatory response by sphingosine 1-phosphate on retinal pigment epithelium cells. *Int. J. Mol. Sci.*, 19: 112, 2017.

187. Suda, K., Murakami, T., Gotoh, N., Fukuda, R., Hashida, Y., Hashida, M., Tsujikawa, A., and Yoshimura, N. High-density lipoprotein mutant eye drops for the treatment of posterior eye diseases. *J. Control. Release*. 266:301–309, 2017.

188. Ivanescu, A.A., Fernández-Robredo, P., Heras-Mulero, H., Sádaba-Echarri, L.M., García-García, L., Fernández-García, V., Moreno-Orduna, M., Redondo-Exposito, A., Recalde, S., and García-Layana, A. Modifying choroidal neovascularization development with a nutritional supplement in mice. *Nutrients*. 7:5423–5442, 2015.

189. Yamada, K., Sakurai, E., Itaya, M., Yamasaki, S., and Ogura, Y. Inhibition of laser-induced choroidal neovascularization by atorvastatin by downregulation of monocyte chemotactic protein-1 synthesis in mice. *Invest. Ophthalmol. Vis. Sci.* 48:1839–1843, 2007.

190. Zambarkaji, H.J., Nakazawa, T., Connolly, E., Lane, A.M., Mallemadugula, S., Kaplan, M., Michaud, N., Hafezi-Moghadam, A., Gragoudas, E.S., and Miller, J.W. Dose-dependent effect of pitavastatin on VEGF and angiogenesis in a mouse model of choroidal neovascularization. *Invest. Ophthalmol. Vis. Sci.* 47:2623–2631, 2006.

191. Gong, Y., Fu, Z., Edin, M.L., Liu, C.H., Wang, Z., Shao, Z., Fredrick, T.W., Saha, N.J., Mors, P.C., Burnim, S.B., Meng, S.S., Lih, F.B., Lee, K.S., Moran, E.P., SantGiovanni, J.P., Helleström, A., Hammad, B.D., Zeldin, D.C., and Smith, L.E. Cytochrome P450 oxidase 2C inhibition adds to o-3 long-chain polyunsaturated fatty acids protection against retinal and choroidal neovascularization. *Arterioscler. Thromb. Vasc. Biol.* 36:1919–1927, 2016.

192. Hayward, C., Shu, X., Cideciyan, A.V., Lennon, A., Barran, P., Zarareparsi, S., Sawyer, L., Hendry, G., Dhillon, B., Milam, A.H., Luthert, P.J., Swaroop, A., Hastie, N.D., Jacobson, S.G., and Wright, A.F. Mutation in a short-chain collagen gene, CTRP5, results in extracellular deposition of glycosaminoglycans with decreased retinal detachment in late-onset retinal degeneration: a genetic model for age-related macular degeneration. *Hum. Mol. Genet.* 12:2657–2667, 2003.

193. Stone, E.M., Lotery, A.J., Munier, F.L., Heon, E., Piguet, B., Guymer, R.H., Vandenburgh, K., Cousin, P., Nishioka, J.P., Bossers, K., Heine, V.M., and Bergen, A.A. The cell biology of the retinal pigment epithelium. *Prog. Retin. Eye Res.* 27:89–93, 2008.

194. Weber, B., Vogt, G., Pruett, R., Stohr, H., and Felbor, U. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby’s fundus dystrophy. *Nat. Genet.* 8:352–356, 1994.

195. Zhang, K., Knaizeva, M., Han, M., Li, W., Ye, Z., Yang, Z., Li, Y., Metzker, M.L., Allikmets, R., Zack, D.J., Kakkuk, K.E., Lagali, P.S., Wong, P.W., MacDonald, I.M., Sieving, P.A., Figueroa, D.J., Austin, C.P., Gould, R.J., Ayyagari, R., and Petruchkin, K. A 5-bp deletion in ELOVL4 is associated with two related forms of autosomal dominant macular dystrophy. *Nat. Genet.* 27:89–93, 2001.

196. Allikmets, R., Shroyer, N.F., Singh, N., Seddon, J.M., Lewis, R.A., Bernstein, P.S., Peiffer, A., Zubriskie, N.A., Li, Y., Hutchinson, A., Dean, M., Lupski, J.R., and Lepper, M. Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. *Science*. 277:1805–1807, 1997.

197. Maeda, A., Golczak, M., Maeda, T., and Palczewski, K. Limited roles of Rdh8, Rdh12, and Abca4 in all-trans-retinal clearance in mouse retina. *Invest. Ophthalmol. Vis. Sci.* 50:5435–5443, 2009.

198. Maeda, A., Maeda, T., Golczak, M., Chou, S., Desai, A., Hoppel, C.L., Matsuyama, S., and Palczewski, K. Involvement of all-trans-retinal in acute light-induced retinopathy of mice. *J. Biol. Chem.* 284:15173–15183, 2009.

199. Mattapallil, M.J., Wawrousek, E.F., Chan, C.C., Zhao, H., Roychoudhury, J., Ferguson, T.A., and Caspi, R.R. The Rd8 mutation of the Crb1 gene is present in vendor lines of C57BL/6N mice and embryonic stem cells, and confounds ocular induced mutant phenotypes. *Invest. Ophthalmol. Vis. Sci.* 53:2921–2927, 2012.

200. Bowes, C., Li, T., Danciger, M., Baxter, L.C., Applebury, M.L., and Farber, D.B. Retinal degeneration in the rd mouse is caused by a defect in the beta subunit of rod cGMP-phosphodiesterase. *Nature*. 347:677–680, 1990.

201. Bowes, C., Li, T., Frankel, W.N., Danciger, M., Coffin, J.M., Applebury, M.L., and Farber, D.B. Localization of a retroviral element within the rd gene coding for the beta subunit of cGMP phosphodiesterase. *Proc. Natl. Acad. Sci. U. S. A.* 90:2955–2959, 1993.

202. Neuner, S.M., Heuer, S.E., Huentelman, M.J., O’Connell, K.M.S., and Kaczorowski, C.C. Harnessing genetic complexity to enhance translatability of Alzheimer’s disease mouse models: a path toward precision medicine. *Neuron*. 101:399–411.e395, 2019.

203. Sundberg, J.P., and Schofield, P.N. Living inside the box: environmental effects on mouse models of human disease. *Dis. Model. Mech.* 11: dmm03560, 2018.

204. Hoshino, A., Ratnapriya, R., Brooks, M.J., Chaitankar, V., Wilken, M.S., Zhang, C., Starostik, M.R., Gieser, L., La Torre, A., Nishio, M., Bates, O., Walton, A., Bermingham-McDonogh, O., Glass, I.A., Wong, R.O.L., Swaroop, A., and Reh, T.A. Molecular anatomy of the developing human retina. *Dev. Cell.* 43:763–779.e764, 2017.

205. Volland, S., Esteve-Rudd, J., Hoo, J., Yee, C., and Williams, D.S. A comparison of some organizational characteristics of the mouse central retina and the human macula. *PLoS One*. 10:e0125631, 2015.

206. Curcio, C.A., Medeiros, N.E., and Millican, C.L. Photoreceptor loss in age-related macular degeneration. *Invest. Ophthalmol. Vis. Sci.* 37:1236–1249, 1996.

207. Huberman, A.D., and Niell, C.M. What can mice tell us about how vision works? *Trends Neurosci.* 34:464–473, 2011.

208. Ingram, N.T., Fain, G.L., and Sampath, A.P. Elevated energy requirement of cone photoreceptors. *Proc. Natl. Acad. Sci. U. S. A.* 117:19599–19603, 2020.

209. Mustafi, D., Kevany, B., Petrukhin, K. A transcriptome analysis reveals rod/cone photoreceptor specific signatures across mammalian retinas. *Hum. Mol. Genet.* 25:4376–4388, 2016.

210. Lakkaraju, A., Umapathy, A., Tan, L.X., Daniele, L., Philp, N.J., Boesze-Battaglia, K., and Williams, D.S. The cell biology of the retinal pigment epithelium. *Prog. Retin. Eye Res.* 2020 [Epub ahead of print]; DOI: 10.1016/j.preteyeres.2020.100846.
parison of mouse and human retinal pigment epithelium gene expression profiles: potential implications for age-related macular degeneration. *PLoS One*. 10:e0141597, 2015.

212. Demetrius, L. Of mice and men. When it comes to studying ageing and the means to slow it down, mice are not just small humans. *EMBO Rep*. 6 Spec No:S39–S44, 2005.

213. Kanow, M.A., Giarmarco, M.M., Jankowski, C.S., Tsan, M., Zhao, Z., Chen, Y., Wang, J., Sternberg, P., Freeman, W., Zheng, W., Reem, R.E., Omarova, S., Huang, S., DiPatre, R.W., Borooah, S., D’Antonio, M., Ayyagari, R., W.W., Borja, V., Aguiar, L.R., Pogue, R., Matsui, H., Vergnes, L., Phan, J., Strauss, M., Tafuri, S., and Reue, K. CETP structure and function: a review. *J. Lipid Res*. 56:81–97, 2015.

214. Gordon, S.M., Li, H., Zhu, X., Shah, A.S., Lu, L.J., and Zheng, W., Mast, N., Saadane, A., and Pikuleva, I.A. Spatial distribution of the pathways of cholesterol homeostasis in human retina. *PLoS One*. 7:e37926, 2012.

215. Ghent, W., Mast, N., Saadane, A., and Pikuleva, I.A. Pathways of cholesterol homeostasis in mouse retina responsive to dietary and pharmacologic treatments. *J. Lipid Res*. 56:1451–1458, 2012.

216. Hogarth, C.A., Roy, A., and Ebert, D.L. Genomic evidence for the absence of a functional cholesteryl ester transfer protein gene in mice and rats. *Comp. Biochem. Physiol. B Biochem. Mol. Biol*. 135:219–229, 2003.

217. Charles, M.A., and Kane, J.P. New molecular insights into CETP structure and function: a review. *J. Lipid Res*. 53:1451–1458, 2012.

218. David, W.S. A comparison of the mouse and human lipoproteome: suitability of the mouse model for studies of human lipoproteins. *J. Proteome Res*. 14:2686–2695, 2015.

219. Bergen, W.G., and Mersmann, H.J. Comparative aspects of lipid metabolism: impact on contemporary research and use of animal models. *J. Nutr*. 135:2499–2502, 2005.

220. Adjiento, J., and Philp, N.J. Cultured primary human fetal retinal pigment epithelium (hRPE) as a model for evaluating RPE metabolism. *Exp. Eye Res*. 126:77–84, 2014.

221. Smith, E.N., D’Antonio-Chronowska, A., Greenwald, W.W., Borja, V., Aguilar, L.R., Pogue, R., Matsu, H., Benaglio, P., Borooah, S., D’Antonio, M., Ayyagari, R., and Frazer, K.A. Human iPSC-derived retinal pigment epithelium: a model system for prioritizing and functionally characterizing causal variants at AMD risk loci. *Stem Cell Reports*. 12:1342-1353, 2019.

222. Toops, K.A., Tan, L.X., and Lakkaraaju, A. A detailed three-step protocol for live imaging of intracellular traffic in polarized primary porcine RPE monolayers. *Exp. Eye Res*. 124:74–85, 2014.

223. Ville, A., Park, Y.K., Secora, C., and Vergara, M.N. Organoids for the study of retinal development and developmental abnormalities. *Front. Cell. Neurosci*. 15:667880, 2021.

224. Zhao, Z., Chen, Y., Wang, J., Sternberg, P., Freeman, M.L., Grossniklaus, H.E., and Cai, J. Age-related retinopathy in NRF2-deficient mice. *PLoS One*. 6:e19456, 2011.

225. Rosenfeld, P.J., Berger, B., Reichel, E., Danis, R.P., Gress, A., Ye, L., Magee, M., Parham, L.R., and McLaughlin, M.M. A Randomized phase 2 study of an anti-amyloid β monoclonal antibody in geographic atrophy secondary to age-related macular degeneration. *Ophthalmol. Retina*. 2:1028–1040, 2018.

226. Edwards, A.O., Ritter, R., 3rd, Abel, K.J., Manning, A., Panhuysen, C., and Carr, L.A. Complement factor H polymorphism and age-related macular degeneration. *Science*. 308:421–424, 2005.

227. Haines, J.L., Hauser, M.A., Schmidt, S., Scott, W.K., Olson, L.M., Gallins, P., Spencer, K.L., Kwan, S.Y., Nouredine, M., Gilbert, J.R., Schnetz-Boutaud, N., Agarwal, A., Postel, E.A., and Pericak-Vance, M.A. Complement factor H variant increases the risk of age-related macular degeneration. *Science*. 308:419–421, 2005.

228. Hageman, G.S., Anderson, D.H., Johnson, L.V., Hancock, L.S., Taiber, A.J., Hardisty, L.L., Hageman, J.L., Stockman, H.A., Borchardt, J.D., Gehrs, K.M., Smith, R.J., Silvestri, G., Russell, S.R., Klaver, C.C., Barbazetto, I., Chang, S., Yannuzzi, L.A., Barile, G.R., Merriam, J.C., Smith, R.T., Osh, A.K., Bergeron, J., Zernant, J., Merriam, J.E., Gold, B., Dean, M., and Allikmets, R. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. *Proc. Natl. Acad. Sci. U. S. A*. 102:7227–7232, 2005.

229. Klein, R.J., Zeiss, C., Chew, E.Y., Tsai, J.Y., Sackler, R.S., Haynes, C., Henning, A.K., SanGiovanni, J.P., Mane, S.M., Mayne, S.T., Bracken, M.B., Ferris, F.L., Ott, J., Barnstable, C., and Hoh, J. Complement factor H polymorphism in age-related macular degeneration. *Science*. 308:385–389, 2005.

230. DiScipio, R.G. Ultrastructures and interactions of complement factors H and I. *J. Immunol*. 149:2592–2599, 1992.

231. Sharma, A.K., and Pangburn, M.K. Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis. *Proc. Natl. Acad. Sci. U. S. A*. 93:10996–11001, 1996.

232. Pickering, M.C., Cook, H.T., Warren, J., Bygrave, A.E., Moss, J., Walport, M.J., and Botto, M. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. *Nat. Genet*. 31:424–428, 2002.

233. Vergnes, L., Phan, J., Strauss, M., Tafuri, S., and Reue, K. Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression. *J. Biol. Chem*. 278:42774–42784, 2003.

234. Hoh Kam, J., Lenassi, E., Malik, T.H., Pickering, M.C., and Jeffery, G. Complement component C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. *Nat. Genet*. 31:424–428, 2002.

235. Faber, C., Williams, J., Juel, H.B., Greenwood, J., Nissen, M.H., and Moss, S.E. Complement factor H deficiency results in decreased neuroretinal expression of Cd59a in aged mice. *Invest. Ophthalmol. Vis. Sci*. 53:6324–6330, 2012.

236. Wang, L., Li, C.M., Rudolf, M., Belyaeva, O.V., Chung, B.H., Kishishvili, N.Y., and Curcio, C.A. Lipoprotein particles of intraocular origin in human Bruch membrane: an unusual lipid profile. *Invest. Ophthalmol. Vis. Sci*. 50:870–877, 2009.

237. Li, C.M., Presley, J.B., Zhang, X., Scott, W.K., Olson, B.H., Medeiros, N.E., Guiry, C., and Curcio, C.A. Retina microsomal triglyceride transfer protein: implications for age-related maculopathy. *J. Lipid Res*. 46:628–640, 2005.
Directional ABCA1-mediated cholesterol efflux and apolipoprotein secretion in the retinal pigment epithelium. *J. Lipid Res.* 59:1927–1939, 2018.

239. Savarase, G., De Ferrari, G., Rosano, G.M., and Perrone-Filardi, P. Safety and efficacy of ezetimibe: a meta-analysis. *Int. J. Cardiol.* 201:247–252, 2015.

240. Kelly, U., Yu, L., Kumar, P., Ding, J.D., Jiang, H., Hageman, G.S., Arshavsky, V.Y., Frank, M.M., Hauser, M.A., and Rickman, C.B. Heparan sulfate, including that in Bruch’s membrane, inhibits the complement alternative pathway: implications for age-related macular degeneration. *J. Immunol.* 185:5486–5494, 2010.

241. Rudolf, M., Curcio, C.A., Schlötzer-Schrehardt, U., Sefat, A.M.M., Tura, A., Aherrahrou, Z., Brinkmann, M., Grisanti, S., Miura, Y., and Ranjbar, M. Apolipoprotein-A-I mimetic peptide L-4F removes Bruch’s membrane lipids in aged nonhuman primates. *Invest. Ophthalmol. Vis. Sci.* 60:461–472, 2019.

242. Raghow, R., Yellaturu, C., Deng, X., Park, E.A., and Elam, M.B. SREBPs: the crossroads of physiological and pathological lipid homeostasis. *Trends Endocrinol. Metab.* 19:65–73, 2008.

243. Wang, B., and Tontonoz, P. Liver X receptors in lipid signalling and membrane homeostasis. *Nat. Rev. Endocrinol.* 14:452–463, 2018.

244. Ory, D.S. Nuclear receptor signaling in the control of cholesterol homeostasis: have the orphans found a home? *Circ. Res.* 95:660–670, 2004.

245. Varga, T., Czinnerzer, Z., and Nagy, L. PPPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. *Biochim. Biophys. Acta.* 1812:1007–1022, 2011.

246. Fares, R.V., Véniat, M.M., Cham, C.M., Flynn, L.M., Pierotti, V., Loring, J.F., Traber, M., Ruland, S., Stokowski, R.S., Huszar, D., and Young, S.G. Phenotypic analysis of mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. *Proc. Natl. Acad. Sci. U. S. A.* 93:6393–6398, 1996.

247. Dikic, I., and Elazar, Z. Mechanism and medical implications of mammalian autophagy. *Nat. Rev. Mol. Cell. Biol.* 19:349–364, 2018.

248. Mitter, S.K., Song, C., Qi, X., Mao, H., Rao, H., Akin, D., Lewin, A., Grant, M., Dunn, W., Ding, J., Bowes Rickman, C., and Boulton, M. Dysregulated autophagy in the RPE is associated with increased susceptibility to oxidative stress and AMD. *Autophagy.* 10:1989–2005, 2014.

249. Dhingra, A., Sharp, R.C., Kim, T., Popov, A.V., Ying, G.S., Pietrofesa, R.A., Park, K., Christofidou-Solomidou, M., and Boesze-Battaglia, K. Assessment of a small molecule synthetic lignan in enhancing oxidative balance and decreasing lipid accumulation in human retinal pigment epithelium. *Int. J. Mol. Sci.* 22:5764, 2021.

250. Zhang, Q., Presswalla, F., Ali, R.R., Zacks, D.N., Thompson, D.A., and Miller, J.M.L. Pharmacologic activation of autophagy without direct mTOR inhibition as a therapeutic strategy for treating dry macular degeneration. *Aging (Albany NY)*. 13:10866–10890, 2021.

251. Houten, S.M., Violante, S., Ventura, F.V., and Wanders, R.J. The biochemistry and physiology of mitochondrial fatty acid β-oxidation and its genetic disorders. *Annu. Rev. Physiol.* 78:23–44, 2016.

252. Fleury, C., Mignotte, B., and Vayssiére, J.L. Mitochondrial reactive oxygen species in cell death signaling. *Biochimie.* 84:131–141, 2002.

253. Seo, S.J., Krebs, M.P., Mao, H., Jones, K., Conners, M., and Lewin, A.S. Pathological consequences of long-term mitochondrial oxidative stress in the mouse retinal pigment epithelium. *Exp. Eye Res.* 101:60–71, 2012.

254. Ro, S., Ma, H.Y., Park, C., Ortogero, N., Song, R., Hennig, G.W., Zheng, H., Lin, Y.M., Moro, L., Hsieh, J.T., and Yan, W. The mitochondrial genome encodes abundant small noncoding RNAs. *Cell Res.* 23:759–774, 2013.

255. Zhao, C., Yasumura, D., Li, X., Matthes, M., Lloyd, M., Nielsen, G., Ahern, K., Snyder, M., Bok, D., Dunaič, J.L., LaVail, M.M., and Vollrath, D. mTOR-mediated dedifferentiation of the retinal pigment epithelium initiates photoreceptor degeneration in mice. *J. Clin. Invest.* 121:369–383, 2011.

256. Rosales, M.A.B., Shu, D.Y., Iacovelli, J., and Saint-Geneix, M. Loss of PGC-1α in RPE induces mesenchymal transition and promotes retinal degeneration. *Life Sci. Alliance.* 2:1–17, 2019.

257. Liu, G.Y., and Sabatini, D.M. mTOR at the nexus of nutrition, growth, ageing and disease. *Nat. Rev. Mol. Cell Biol.* 21:183–203, 2020.

258. Huang, J., Gu, S., Chen, M., Zhang, S.J., Jiang, Z., Chen, X., Jiang, C., Liu, G., Radu, R.A., Sun, X., Vollrath, D., Du, J., Yan, B., and Zhao, C. Abnormal mTORC1 signaling leads to retinal pigment epithelium degeneration. *Theranostics.* 9:1170–1180, 2019.

259. Rajala, A., Wang, Y., and Rajala, R.V.S. Constitutive activation mutant mTOR promote cone survival in retinitis pigmentosa mice. *Adv. Exp. Med. Biol.* 707:491–497, 2018.

260. Lin, B., Xiong, G., and Yang, W. Ribosomal protein S6 kinase 1 promotes the survival of photoreceptors in retinitis pigmentosa. *Cell Death Dis.* 9:1141, 2018.

261. Venkatesh, A., Ma, S., Le, Y.Z., Hall, M.N., Ruegg, M.A., and Punzo, C. Activated mTORC1 promotes long-term cone survival in retinitis pigmentosa mice. *J. Clin. Invest.* 125:1446–1458, 2015.

262. Punzo, C., Kornacker, K., and Cepko, C.L. Stimulation of the insulin/mTOR pathway delays cone death in a mouse model of retinitis pigmentosa. *Cell Death Dis.* 10:1989, 2014.

263. Yagasaki, R., Nakahara, T., Mori, A., Sakamoto, K., and Ishii, K. Effects of mTOR inhibition on normal retinal vascular development in the mouse. *Exp. Eye Res.* 129:127–134, 2014.

264. Morita, M., Gravel, S.P., Hulea, L., Larsson, O., Pollak, M., St-Pierre, J., and Topisirovic, I. mTOR coordinates protein synthesis, mitochondrial activity and proliferation. *Cell Cycle.* 14:473–480, 2015.

265. Starr, C.R., Nyankerh, C.N.A., Qi, X., Hu, Y., Gorbatyuk, O.S., Sonenberg, N., Boukht, M.E., and Gorbatyuk, M.S. Role of translational attenuation in inherited retinal degeneration. *Invert. Ophthalmol. Vis. Sci.* 60:4849–4857, 2019.

266. Molday, L.L., Rabin, A.R., and Molday, R.S. ABCR expression in foveal cone photoreceptors and its role in Stargardt macular dystrophy. *Nat. Genet.* 25:257–258, 2000.

267. Illing, M., Molday, L.L., and Molday, R.S. The 220-kDa rim protein of retinal rod outer segments is a member of the ABC transporter superfamily. *J. Biol. Chem.* 272:10303–10310, 1997.
268. Sun, H., and Nathans, J. Stargardt’s ABCR is localized to the disc membrane of retinal rod outer segments. *Nat. Genet.* 17:15–16, 1997.

269. Tsybovsky, Y., Molday, R.S., and Palczewski, K. The ATP-binding cassette transporter ABCA4: structural and functional properties and role in retinal disease. *Adv. Exp. Med. Biol.* 703:105–125, 2010.

270. Kim, S.R., Jang, Y.P., Jockusch, S., Fishkin, N.E., Turro, N.J., and Sparrow, J.R. The all-trans-retinal dimer series of lipofuscin pigments in retinal pigment epithelial cells in a recessive Stargardt disease model. *Proc. Natl. Acad. Sci. U. S. A.* 104:19273–19278, 2007.

271. Mata, N.L., Weng, J., and Travis, G.H. Biosynthesis of a major lipofuscin fluorophore in mice and humans with ABCR-mediated retinal and macular degeneration. *Proc. Natl. Acad. Sci. U. S. A.* 97:7154–7159, 2000.

272. Anderson, D.M.G., Ablonczy, Z., Koutalos, Y., Hanneken, K.A., Delton-Vandenbroucke, I. Bis(monoacylglycerophosphate, a peculiar phospholipid to control the fate of cholesterol: implications in pathology. *Prostaglandins Leukot. Essent. Fatty Acids.* 81:313–324, 2009.

273. Kaur, G., Tan, L.X., Rathnasamy, G., La Cuunza, N., Germer, C.J., Toops, K.A., Fernandes, M., Blenkinsop, T.A., and Lakkaraju, A. Aberrant early endosome biogenesis mediates complement activation in the retinal pigment epithelium in models of macular degeneration. *Proc. Natl. Acad. Sci. U. S. A.* 115:9014–9019, 2018.

274. Logan, S., and Anderson, R.E. Dominant stargardt macular dystrophy (STGD3) and ELOVL4. *Adv. Exp. Med. Biol.* 801:447–453, 2014.

275. Logan, S., Agbaga, M.P., Chan, M.D., Kabir, N., Mandal, N.A., Brush, R.S., and Anderson, R.E. Deciphering mutant ELOVL4 activity in autosomal-dominant Stargardt macular dystrophy. *Proc. Natl. Acad. Sci. U. S. A.* 110:5446–5451, 2013.

276. Yu, M., Benham, A., Logan, S., Brush, R.S., Mandal, M.N., Anderson, R.E., and Agbaga, M.P. ELOVL4 protein preferentially elongates 20:5n3 to very long chain PUFAs over 20:4n6 and 22:6n3. *J. Lipid Res.* 53:494–504, 2012.

277. Choi, R., Gorusupudi, A., and Bernstein, P.S. Long-term follow-up of autosomal dominant Stargardt macular dystrophy (STGD3) subjects enrolled in a fish oil supplement interventional trial. *Ophthalmic Genet.* 39:307–313, 2018.

278. Li, F., Marchette, L.D., Brush, R.S., Elliott, M.H., Le, Y.Z., Henry, K.A., Anderson, A.G., Zhao, C., Sun, X., Zhang, K., and Anderson, R.E. DHA does not protect ELOVL4 transgenic mice from retinal degeneration. *Mol. Vis.* 15:1185–1193, 2009.

279. Dornstauder, B., Suh, M., Kuny, S., Gaillard, F., Macdonald, I.M., Clandinin, M.T., and Sauvé, Y. Dietary docosahexaenoic acid supplementation prevents age-related functional losses and A2E accumulation in the retina. *Invest. Ophthalmol. Vis. Sci.* 53:2256–2265, 2012.

280. Harkewicz, R., Du, H., Tong, Z., Alkurraya, H., Bedell, M., Sun, W., Wang, X., Hsu, Y.H., Esteve-Rudd, J., Hughes, G., Su, Z., Zhang, M., Lopes, V.S., Molday, R.S., Williams, D.S., Dennis, E.A., and Zhang, K. Essential role of ELOVL4 protein in very long chain fatty acid synthesis and retinal function. *J. Biol. Chem.* 287:11469–11480, 2012.

281. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. *JAMA.* 309:2005–2015, 2013.

282. Gordon, D.J., Probstfield, J.L., Garrison, R.J., Neaton, J.D., Castelli, W.P., Knoke, J.D., Jacobs, D.R., Bangdiwala, S., and Tyrold, H.A. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. *Circulation.* 79:8–15, 1989.

283. Fisher, E.A., Feig, J.E., Hewing, B., Hazen, S.L., and Smith, J.D. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. *Arterioscler. Thromb. Vasc. Biol.* 32:2813–2820, 2012.

284. Watson, C.E., Weissbach, N., Kjems, L., Ayalaosamujula, S., Zhang, Y., Chang, I., Navab, M., Hama, S., Hough, G., Reddy, S.T., Soffer, D., Rader, D.J., Fogelman, A.M., and Schetter, A. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. *J. Lipid Res.* 52:361–373, 2011.

285. Zheng, K.H., Kaiser, Y., van Olden, C.C., Santos, R.D., Dasseux, J.L., Genest, J., Gaudet, D., Westerink, J., Keyserling, C., Verberne, H.J., Leitersdorf, E., Hegele, R.A., Descamps, O.S., Hopkins, P., Nederveen, A.J., and Stroes, E.S.G. No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. *Atherosclerosis.* 311:13–19, 2020.

286. Tardif, J.C., Ballantyne, C.M., Barter, P., Dasseux, J.L., Fayad, Z.A., Guertin, M.C., Kastelein, J.J., Keyserling, C., Kepp, H., Koenig, W., L’Allier, P.L., Lespérance, J., Lüscher, T.F., Paolini, J.F., Tawakol, A., Waters, D.D., and Can HDL Infusions Significantly Quiicken Atherosclerosis REgression (CHI-SQUARE) Investigators. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. *Eur. Heart J.* 35:3277–3286, 2014.

287. Dunbar, R.L., Movva, R., Bloedon, L.T., Duffy, D., Norris, R.B., Navab, M., Fogelman, A.M., and Rader, D.J. Oral apolipoprotein A-I mimetic D-4F lowers HDL-inflammatory index in high-risk patients: a first-in-human multiple-dose, randomized controlled trial. *Clin. Transl. Sci.* 10:455–469, 2017.

288. Rudolf, M., Mir Mohi Sefat, A., Miura, Y., Tura, A., Raasch, W., Ranjbar, M., Jacobs, R., Anantharamaiah, G.M., and Cerci, C.A. ApoA-I mimetic peptide 4F reduces age-related lipid deposition in murine Bruch’s membrane and causes its structural remodeling. *Curr. Eye Res.* 43:135–146, 2018.

289. Su, F., Spee, C., Araujo, E., Barron, E., Wang, M., Ghione, C., Hinton, D.R., Nusinowitz, S., Kannan, R., Reddy, S.T., and Faris-Eisner, R. A novel HDL-mimetic
peptide HM-10/10 protects RPE and photoreceptors in murine models of retinal degeneration. *Int. J. Mol. Sci.* 20: 4807, 2019.

292. Ma, W., Zhang, Y., Gao, C., Fariss, R.N., Tam, J., and Wong, W.T. Monocyte infiltration and proliferation re-establish myocardial cell homeostasis in the mouse retina following retinal pigment epithelial cell injury. *Sci. Rep.* 7:8433, 2017.

293. Yu, C., Roubeix, C., Sennlaub, F., and Saban, D.R. Microglia versus monocytes: distinct roles in degenerative diseases of the retina. *Trends Neurosci.* 43:433–449, 2020.

294. Zhou, Q., and Liao, J.K. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. *Curr. Pharm. Des.* 15:467–478, 2009.

295. Barbosa, D.T., Mendes, T.S., Cintron-Colon, H.R., Wang, S.Y., Bhislituk, R.B., Singh, K., and Lin, S.C. Age-related macular degeneration and protective effect of HMG Co-A reductase inhibitors (statins): results from the National Health and Nutrition Examination Survey 2005–2008. *Eye (Lond).* 28:472–480, 2014.

296. Wilson, H.L., Schwartz, D.M., Bhatt, H.R., McCulloch, J.W., Ganotakis, E., Loewenstein, J.I., Young, L.H., Gragoudas, E.S., Eliott, D., Kim, I.K., Tsilimbaris, M.K., and Miller, J.W. Regression of some high-risk features of age-related macular degeneration (AMD) in patients receiving intensive statin treatment. *EBioMedicine.* 5:198–203, 2016.

297. Guymer, R.H., Baird, P.N., Varsamidis, M., Busija, L., Dimitrov, P.N., Aung, K.Z., Makeyeva, G.A., Richardson, A.J., Lim, L., and Robman, L.D. Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration. *PLoS One.* 8:e83759, 2013.

298. Vavvas, D.G., Daniels, A.B., Kapsala, Z.G., Goldfarb, J.W., Ganotakis, E., Loewenstein, J.I., Young, L.H., Gragoudas, E.S., Eliott, D., Kim, I.K., Tsilimbaris, M.K., and Miller, J.W. Regression of some high-risk features of age-related macular degeneration (AMD) in patients receiving intensive statin treatment. *EBioMedicine.* 5:198–203, 2016.

299. Agroán, E., Clemons, T.E., Lee, H., Jeon, H.L., Park, S.J., and Shin, J.Y. Effect of statin exposure on choroidal neovascularization among patients with age-related macular degeneration. *Br. J. Ophthalmol.* 112:488–494, 2005.

300. Wilson, H.L., Schwartz, D.M., Bhatt, H.R., McCulloch, C.E., and Duncan, J.L. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. *Am. J. Ophthalmol.* 137:615–624, 2004.

301. Lee, H., Jeon, H.L., Park, S.J., and Shin, J.Y. Effect of statins, mefloquine, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers on age-related macular degeneration. *Yonsei Med. J.* 60:679–686, 2019.

302. Al-Holou, S.N., Tucker, W.R., Agrón, E., Clemons, T.E., Cukras, C., Ferris, F.L., Chew, E.Y., and Age-Related Eye Disease Study 2 Research Group. The association of statin use with age-related macular degeneration progression: the age-related eye disease study 2 report number 9. *Ophthalmology.* 122:2490–2496, 2015.

303. Mandas, A., Mereu, R.M., Catte, O., Saba, A., Serchisu, L., Costaggiu, D., Peiretti, E., Caminiti, G., Vinci, M., Casu, M., Piiludu, S., Fossarello, M., Manconi, P.E., and Dessì, S. Cognitive impairment and age-related vision disorders: their possible relationship and the evaluation of the use of aspirin and statins in a 65-years-and-over sardinian population. *Front. Aging Neurosci.* 6:309, 2014.

304. Klein, R., Myers, C.E., Buitendijk, G.H., Rochnittch, E., Gao, X., de Jong, P.T., Sivakumar, T.A., Burtluksky, G., McKeen-Cowdin, R., Hofman, A., Iyengar, S.K., Lee, K.E., Stricker, B.H., Vingerling, J.R., Mitchell, P., Klein, B.E., Klaver, C.C., and Wang, J.I. Lipids, lipid genes, and incident age-related macular degeneration: the three continent age-related macular degeneration consortium. *Am. J. Ophthalmol.* 158:513–524.e513, 2014.

305. Shalev, V., Sror, M., Goldshtein, L., Kokia, E., and Chodic, G. Statin use and the risk of age related macular degeneration in a large health organization in Israel. *Ophthalmic Epidemiol.* 18:83–90, 2011.

306. Fong, D.S., and Contreras, R. Recent statin use and 1-year incidence of exudative age-related macular degeneration. *Am. J. Ophthalmol.* 149:955–958.e951, 2010.

307. Klein, R., Knudtson, M.D., and Klein, B.E. Statin use and the five-year incidence and progression of age-related macular degeneration. *Am. J. Ophthalmol.* 144:1–6, 2007.

308. Tamil, J.S., Mitchell, P., Rochnittch, E., and Wang, J.J. Statins and the long-term risk of incident age-related macular degeneration: the Blue Mountains Eye Study. *Am. J. Ophthalmol.* 143:685–687, 2007.

309. Miller, J.W. Regression of some high-risk features of age-related macular degeneration (AMD) in patients receiving intensive statin treatment. *EBioMedicine.* 5:198–203, 2016.

310. Rajeshuni, N., Ludwig, C.A., and Moshfeghi, D.M. The effect of statin exposure on choroidal neovascularization in nonexudative age-related macular degeneration patients. *Eye (Lond).* 33:163–165, 2019.

311. VanderBeek, B.L., Zacks, D.N., Talwar, N., Nan, B., and Stein, J.D. Role of statins in the development and progression of age-related macular degeneration. *Retina.* 33: 414–422, 2013.

312. Lee, H., Jeon, H.L., Park, S.J., and Shin, J.Y. Effect of statins, mefloquine, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers on age-related macular degeneration. *Yonsei Med. J.* 60:679–686, 2019.

313. Al-Holou, S.N., Tucker, W.R., Agrón, E., Clemons, T.E., Cukras, C., Ferris, F.L., Chew, E.Y., and Age-Related Eye Disease Study 2 Research Group. The association of statin use with age-related macular degeneration progression: the age-related eye disease study 2 report number 9. *Ophthalmology.* 122:2490–2496, 2015.

314. Ryeom, S.W., Sparrow, J.R., and Silverstein, R.L. CD36 participates in the phagocytosis of rod outer segments by retinal pigment epithelial cells. *J. Cell Sci.* 109:387–395, 1996.

315. Yamada, Y., Tian, J., Yang, Y., Cutler, R.G., Wu, T., Telljohann, R.S., Mattson, M.P., and Handa, J.T. Oxidized low density lipoproteins induce a pathologic response by retinal pigment epithelial cells. *J. Neurochem.* 105: 1187–1197, 2008.
endothelial growth factor-to-pigment epithelium-derived factor ratio in human retinal pigment epithelial cells. *Curr. Eye Res.* 36:379–385, 2011.

319. Ebrahimi, K.B., Fijalkowski, N., Cano, M., and Han-da, J.T. Decreased membrane complement regulators in the retinal pigmented epithelium contributes to age-related macular degeneration. *J. Pathol.* 229:729–742, 2013.

320. Gnanaguru, G., Choi, A.R., Amarnani, D., and D’Amore, P.A. Oxidized lipoprotein uptake through the CD36 receptor activates the NLRP3 inflammasome in human retinal pigment epithelial cells. *Invest. Ophthalmol. Vis. Sci.* 57:4704–4712, 2016.

321. Yu, A.L., Lorenz, R.L., Haritoglou, C., Kampik, A., and Welge-Lussen, U. Biological effects of native and oxidized low-density lipoproteins in cultured human retinal pigment epithelial cells. *Exp. Eye Res.* 88:495–503, 2009.

322. Yating, Q., Yuan, Y., Wei, Z., Qing, G., Xingwei, W., Qu, Q., and Lili, Y. Oxidized LDL induces apoptosis of human retinal pigment epithelium through activation of ERK-Bax/Bcl-2 signaling pathways. *Curr. Eye Res.* 40:415–422, 2015.

Received: July 29, 2021
Accepted: September 14, 2021

Address correspondence to:
Dr. Catherine Bowes Rickman
Department of Ophthalmology
Duke University Medical Center
Box 3802 AERI Rm 5010
Durham, NC 27710
USA

E-mail: bowes007@duke.edu